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Abstract 
 
Notch Signaling is one of the important signaling pathway in the development of T-
Lymphocytes . Its role as transcriptional regulator during the development of T-cells has  
been well established. Also, it has been well established that miRNAs are responsible for 
the regulation of many important cellular functions, but the transcriptional regulators of 
miRNAs have been poorly understood. In order to identify microRNAs regulated by 
oncogenic Notch3 signaling, we performed microarray-based miRNA profiling of T-cell 
acute lymphoblastic leukemia (T-ALL) models, differentially expressing Notch3. We 
identified 7 miRNAs to be regulated by Notch3 modulation in different models. Among 
them, miR-223 putative promoter analysis revealed a conserved CSL/RBPJκ binding site 
which was nested to p65. Luciferase & ChIP assays on wild type and mutated promoter of 
miR-223 showed direct regulation by NFκB (p65) and indirect regulation by Notch3 
transcriptional complex. We also demonstrated that tumor suppressor FBXW7 is regulated 
by miR-223, and analysed its oncogenic effects on cell growth and cell cycle by 
overexpression or knockdown of miR-223. Moreover we saw an increase in miR-223 
expression and NFκB activation in GSI resistant T-ALL cell lines treated with GSI, 
without affecting their proliferation rate. The same cell lines deleted for NFκB pathway, 
showed less expression of miR-223 when compared with wild type and lost their ability to 
resist GSI treatment, suggesting the involvement of miR-223 in the mechanism of GSI 
resistivity. Thus we conclude that miR-223 has an oncogenic role in Notch3 induced T-
Cell Acute Lymphoblastic Leukemia and could play a significant role in GSI resistivity.  
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1 Introduction 
1.1 Notch Signaling pathway. 
1.1.1 General 
Notch signaling is one of the fundamental signaling mechanisms essential for proper 
embryonic development, cell fate specification, and stem cell maintenance. The Notch gene 
was discovered almost 90 years ago by Morgan and colleagues in Drosophila, who observed 
that X-linked dominant mutations in Drosophila caused irregular Notches at the wing margin 
The study of the embryonic lethal phenotype caused by complete lack of Notch function [1]. 
and its complex allelic series and genetic interactions [2] brought Notch to the forefront, so 
that in the mid-1980s the Drosophila Notch gene product was identified [3] [4]. Notch is a 
local signaling mechanism that is evolutionarily conserved throughout the animal kingdom. In 
Drosophila, Notch encodes a receptor that is activated by two different membrane bound 
ligands called Delta and Serrate. Mammals have four Notches (Notch1-4) (Figure 1) and five 
ligands: Delta-like-1, Delta-like-3, Delta-like-4, Jagged-1 and Jagged-2 (Figure 2)  
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1.1.2 Components of Notch signaling Pathway 
A large number of studies, mainly conducted on Drosophila, Caenorhabditis and vertebrates, 
have characterized the molecular properties and functions of the main components and 
auxiliary factors of the Notch pathway. These are strongly conserved in bilaterians . Both, the 
Notch receptors and its ligands are type I transmembrane proteins with a modular 
architecture. The core components include: i) metalloproteases ADAM 10 and 17 (involved in 
the second cleavage (S2) after ligand binding) [5] [6] [7] ii) γ-secretase complex (Presenilin-
Nicastrin-APH1-PEN2) (involved in the final cleavage (S3)) and iii) Co-repressor complex 
composed of CBF1, Su(H), Lag-1)/Ncor/SMRT/Histone Deacetylase (HDAC) . In addition to 
these core components of the Notch pathway, several other proteins are involved in the Notch 
signalling regulation in several cellular contexts, and act either on the Notch receptor or on 
the ligand DSL. Some of these regulators modulate the amount of receptor available for 
signalling [8]. Numb, the NEDD4/Su(dx) E3 ubiquitin ligases, and Notchless are important 
negative regulators, while Deltex is considered to antagonize NEDD4/Su(dx) and therefore to 
be an activator of Notch signaling [9]. Strawberry Notch (Sno), another modulator of the 
pathway whose role is still unclear, seems to be active downstream and disrupts the CSL 
repression complex [10]. Regulation may also occur at the level of ligand activity via the E3 
ubiquitin ligases Neuralized and Mindbomb [11, 12]. The list of the components of Notch 
signaling pathway has been mentioned in Table1 for references. 
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Table .1   
Different Components involved in Notch Signalling Pathway 
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1.1.3 Biogenesis of Notch receptor 
The Notch receptors are synthesized as single precursor proteins that are proteolytically 
cleaved in the Golgi (at site S1) during their transport to the cell surface by a furin-like 
protease. This cleavage generates a heterodimeric receptor consisting of a Notch Extracellular 
subunit (N
EC
) that is noncovalently linked to a second subunit containing the extracellular 
heterodimerization domain and the transmembrane domain followed by the cytoplasmic 
region of the Notch receptor. The extracellular part of the receptors contains 29-36 epidermal 
growth factor (EGF)  like repeats involved in ligand binding, followed by three cysteine-rich 
LIN12 repeats that prevent ligand-independent activation and a hydrophobic stretch of amino 
acids mediating heterodimerization between N
EC
 and Notch Intracellular Domain (N
ICD
). The 
cytoplasmic tail of the receptor also known as N
ICD
 harbors multiple conserved elements 
including nuclear localization signals, as well as protein-protein interaction and 
transactivation domains. N
ICD
 contains a RAM23 domain [13] six ankyrin/cdc10 repeats 
involved in protein-protein interactions [14], two nuclear localization signals (N1 and N2), a 
transcriptional activation domain (TAD) that differs among the four receptors, and a PEST 
sequence [rich in proline (P), glutamic acid (E), serine (S) and threonine (T)] that negatively 
regulates protein stability [15]  
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Figure 1: Structure of Notch receptors in Drosophila and mammals. Diagrammatic representation 
of the Drosophila Notch (dNotch) receptor and the four known mammalian receptors. The Notch 
proteins are expressed on the cell surface as heterodimers composed of a large extracellular domain 
non-covalently linked to the intracellular domain. The extracellular domain of all Notch receptors 
contains epidermal growth-factor-like repeats (EGFLR) and three LIN Notch (LNR) repeats. The 
intracellular domain contains the RAM23 domain and seven Ankyrin/CDC10 repeats (ANK), 
necessary for protein- protein interactions. In addition, Notch receptors 1-3 contain two nuclear 
localization signals (NLS) compared to one NLS in Notch4. The NSL is necessary to target the 
intracellular domain to the nucleus where the transcriptional activation domain (TAD) activates 
downstream events. All four Notch receptors contain a C-terminal Pro Glu Ser Thr (PEST) sequence 
for degradation. 
 
 
 
 
 
Figure 2: Structure of the DSL ligands in Drosophila and mammals. Mammals have five DSL 
family members. Delta-like 1, 3 and 4 are homologs of Drosophila Delta (dDelta), while Jagged1 and 
2 are homologous to Drosophila Serrate (dSerrate). DSL ligands are transmembrane proteins of which 
the extracellular domain contains a characteristic number of EGF-like repeats and a cysteine rich N-
terminal DSL domain. The DSL domain is a conserved motif found in all DSL ligands and required 
for their interaction with Notch. Serrate, Jagged1, and Jagged2 contain an additional cysteine rich 
domain (CRD). 
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1.1.4 Mechanism of Notch Signalling 
Notch signaling is initiated by ligand-receptor interaction between neighboring cells (Figure 
3), leading to two successive proteolytic cleavages of the receptor. The first is mediated by 
metalloproteases of the ADAM family, which cleave the receptors 12–13 amino acids 
external to the transmembrane domain. The second cleavage is mediated by γ-secretase, a 
complex that contains presenilin, niscartin, PEN2 and APH1 [8]. The shedded extracellular 
domain is endocytosed by the ligand-expressing cell, a process that is dependent on 
monoubiquitinylation of the cytoplasmic tail of the ligands by E3-ubiquitin. N
ICD
 then 
translocates to the nucleus and acts as a transcriptional co-activator. N
ICD
 cannot bind directly 
to DNA, but heterodimerizes with the DNA binding protein RBPJκ (recombination signal 
sequence-binding protein Jk, also called CSL, CBF1, Su(H) and LAG-1) and activates 
transcription of genes containing RBPJκ binding sites. Interestingly, RBPJκ was originally 
identified as a repressor of transcription by Vales and colleagues [16]. The RBPJκ mediated 
repression could be relieved by the recruitment of distinct transcription factor such as Notch. 
Thus the RBPJκ activator/repressor paradox was resolved with the realization that repression 
and activation via RBPJκ involves the recruitment of specific protein complexes, which 
influence the transcription of target genes in a positive or negative fashion. In the absence of 
ligand, hence without nuclear N
ICD
, RBPJκ is retained at the gene regulatory elements of 
Notch target genes repressing their transcription, through the recruitment of corepressor 
complexes. Transcriptional repression seems to be mediated by different mechanisms. Based 
on biochemical experiments, it was proposed that RBPJκ can interact directly with TFIID, or 
can recruit histone deacetylase-containing complexes. Previously, at least three different 
interactions between RBPJκ and corepressor complexes have been described: i) a complex 
containing SMRT/mSin3A/ HDAC-1 (SMRT, Silencing Mediator for Retinoic acid and 
Thyroid hormone receptor; HDAC-1, histone deacetylase-1) or ii) NCoR/mSin3A/HDAC-1 
complex and a iii) CIR/SAP30/HDAC-2 complex. So far, the functional relevance of these 
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biochemical findings still remains to be seen. Recently it was characterized that the  RBPJκ-
associated repressor complex is composed of corepressors RBPJκ, SHARP (SMRT and 
HDAC associated repressor protein), CtBP (C-terminal binding protein) and CtIP (CtBP 
interacting protein). N
ICD
 binding to RBPJκ is crucial for the switch from repressed to 
activated state. N
ICD
 first displaces corepressors from RBPJκ, resulting in derepression of 
promoters and subsequently recruits a coactivator complex to activate the transcription of 
Notch target genes. In the initial phase of transcriptional activation complex assembly, N
ICD
 
forms multimers. Subsequently, the N
ICD
 multimer forms a complex with Skip, which then 
provides a docking site to recruit Maml1 and forms a pre-activation complex. The interaction 
between the pre-activation complex and CSL results in formation of  the transcriptional 
activation complex on DNA. Mastermind is a glutamine-rich transcriptional co-activator 
protein that is localized to the nucleus [17], [18]. A short, approximately 75-residue,N-
terminal domain of Mastermind is required for binding to the CSL- N
ICD
 complex, which 
additionally requires the three conserved domains of CSL (NTD, BTD, and CTD) and the 
ANK domain of N
ICD
. Mastermind has dual roles of both activating Notch target gene 
transcription through the direct binding of CBP/p300 and promoting hyperphosphorylation 
and degradation of N
ICD
. 
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Mechanism of Notch Signalling (Canonical) 
 
Figure 3: Summary of the main features of Notch signalling. Three proteolytic cleavage steps are 
required for canonical Notch receptor signalling. The first proteolytic cleavage step (S1 cleavage) is 
mediated by Furin, occurs in the trans-Golgi and produces a heterodimer composed of a ligand-
binding Notch extracellular domain (N
ECD
) and a single-pass transmembrane signalling domain 
referred to as the Notch intracellular domain (N
ICD
). The functional importance of this cleavage is still 
somewhat unclear. The association of N
ECD
 and the transmembrane portion of the receptor heterodimer 
is dependent on non-covalent interactions. Pathway activation occurs when the N
ECD
 binds to Delta– 
Serrate–LAG2 (DSL) ligands that are expressed on the membrane of neighbouring cells. This trans 
interaction results in the second proteolytic event (S2 cleavage) of the Notch receptor, which clears 
most of the N
ECD
 from the outer portion of the membrane, a process mediated by the TACE (also 
known as ADAM17) metalloproteinase. The N
ECD
 is subsequently released and internalized through 
endocytosis by the ligand-expressing cell, where it undergoes lysosomal degradation. Subsequently, 
γ-secretase cleaves the tethered receptor near the inner leaflet of the membrane (S3 cleavage) in the 
Notch-expressing cell, producing the transcriptionally active N
ICD
, which translocates to the nucleus 
through a poorly understood process. In the nucleus, the N
ICD
 interacts with Drosophila melanogaster 
Suppressor of Hairless (SU(H)) and the transcriptional co-activator, Mastermind (MAM) — the 
mammalian orthologues of which are CBF1–SU(H)–LAG1 (CSL) and Mastermind-like (MAML) 
proteins, respectively — thereby inducing transcription of target genes, by converting CSL into a 
transcription activator through the exchange of co-repressors for co-activators. Many Notch target 
genes encode transcriptional regulators, which influence cell-fate decisions through the regulation of 
basic helix–loop–helix hairy and enhancer of split (HES) proteins: Hairy and Enhancer of split 
(E(SPL)) in D. melanogaster and their mammalian orthologues HES1 and HES5. The HES proteins 
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subsequently regulate the expression of genes involved in Notch-dependent cell-fate determination, 
such as apoptosis, proliferation or differentiation. By contrast, expression of ligands and the Notch 
receptor on the same cells results in cis inhibition of Notch signals and receptor degradation. 
Recycling the receptor through the endocytic pathway has been shown to be important for receptor and 
ligand maturation, non-canonical signalling and degradation (BOX 2). Notch activity is regulated by 
ubiquitylation of nuclear N
ICD
 by the E3 ubiquitin ligases, SEL-10 in Caenorhabditis elegans and 
Suppressor of Deltex (SU(DX)) in D. melanogaster, leading to N
ICD
 degradation, thus allowing the 
cell to become ligand-competent once again. The ubiquitylation status of the receptor (by Kurtz, 
Deltex and Shrub) in the multi-vesicular bodies can also determine whether Notch continues to signal 
or undergoes proteasomal degradation. Additionally, signal attenuation is achieved through lysosomal 
degradation of the N
ICD
. 
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1.1.5 Notch Signalling in Multipotent Haematopoietic Cells 
The first definitive hematopoietic stem cells (HSCs) capable of generating adult-type 
erythrocytes, myeloid and lymphoid cells arise in murine embryos at around embryonic day 
9.5 and express Notch1, Notch2, and Notch 4 [19]. However, Notch1, but not Notch2, is 
required to generate definitive HSCs during embryonic development. The Scl, Gata2 and 
Runx1 genes, which encode transcription factors required for definitive hematopoiesis, are 
down-regulated in Notch1
−/−
 [19] and CSL
−/− 
[20] embryonic HSCs, suggesting that 
Notch1/CSL-dependent signaling regulates their induction. Functions of Notch signaling in 
postnatal HSC self-renewal and maintenance have been less clear. Notch ligands in vitro, or 
overexpressing both the constitutively active Notch alleles [21], [22] [23], or the Notch 
downstream targets such as Hes1 [24], [25], have suggested that Notch increases self-renewal 
and decreases differentiation of hematopoietic progenitors. Moreover, genetic manipulations 
that appear to increase Jagged1 expression in bone marrow stem cell niches enhance self-
renewal of adult HSCs [26]. However, the notion that Notch signaling critically regulates 
HSC self-renewal in vivo has not been clearly supported by loss-of-function data. For 
example, conditional ablation of Notch1 or Jagged1 did not reveal defects in HSC 
maintenance even in competitive reconstitution assays [27] , but potential functional 
redundancy with other Notch ligands and receptors could not be excluded. Nonetheless, HSCs 
lacking CSL, which therefore lack all canonical Notch signaling, generate normal numbers of 
short-lived myeloid cells [28], suggesting that HSC maintenance is not compromised by loss 
of Notch signaling. Globally inactivating canonical Notch signaling in HSCs by expressing a 
mutant version of the co-activator MAML, which binds N
ICD
 to dominantly inhibit CSL-
dependent Notch activation, revealed that canonical Notch signaling is dispensable in 
maintaining adult HSCs, contradicting an earlier study that concluded that CSL-dependent 
Notch activation enhances adult HSC differentiation at the expense of self-renewal [29]. 
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Although dispensable for HSC maintenance, recent in vitro and in vivo data strongly 
implicate Notch signaling in early stages of myeloerythroid differentiation. HSCs cultured 
with OP9 bone marrow stromal cells expressing Dll1 underwent CSL-dependent 
megakaryocyte specification [30]. Fresh ex vivo megakaryocyte-erythrocyte precursors 
expressed Notch4 and several direct Notch target genes, indicating, Notch4 as a possible 
mediator of Notch-induced megakaryocyte development. However, neither the Notch 
receptor(s) nor ligand(s) that drives this hematopoietic outcome in vivo was identified. 
Interestingly, recent evidence implicates dysregulated activation of CSL-dependent Notch 
signaling in acute megakaryoblastic leukemia [31]. In multipotent progenitors that have lost 
erythro-megakaryocytic potential, maintenance of Notch1 expression is part of a lymphoid 
specification program induced by transcription factors such as Ikaros, PU.1, E2A, and Mef2c 
[32], [33], [34] [35]. Notch1 expression in such lymphoid-primed multipotent progenitors 
(LMPPs) specifically depends on E2A [34], [36],and perhaps also on Ikaros [37]. Current 
evidence indicates that thymus-seeding progenitors reside within a Flt3+ and CCR9+ subset 
of early lymphoid-biased progenitors in the bone marrow [38], [39]. As discussed further, 
Notch1 is specifically required to generate intrathymic T cell precursors, but is dispensable 
for B lymphoid and myeloid cell development in bone marrow. Therefore, Notch1 expression 
in pre-thymic T cell progenitors such as LMPPs likely represents one of the earliest events in 
specification of the T cell lineage. Given that several Notch ligands are expressed in the bone 
marrow [40], there must be some mechanisms to prevent LMPPs from activating Notch1 and 
generating T cells prior to thymic seeding. Indeed, Notch1 activation and T cell development 
in bone marrow progenitors are actively repressed by the lymphoma-related transcriptional 
repressor [41]. This repression can apparently be overcome by retroviral expression of Dll4 in 
bone marrow cells, which induces ectopic T cell development up to the CD4/CD8 double-
positive (DP) stage in the bone marrow [42], [43]. Importantly, these and previous studies 
[44], [45], [46] demonstrated that with the exception of failing to promote robust Notch1 
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activation, the bone marrow provides a suitable microenvironment for supporting T 
lymphopoiesis. Interestingly, Notch/CSL signaling promotes T cell development up to the DP 
stage in the spleen and lymph nodes of irradiated mice, but this process appears to be 
suppressed in the absence of lymphopenia [47]. This extrathymic T cell development may 
have therapeutic relevance in a bone marrow transplantation setting. Additional studies are 
needed to identify the Notch receptors and ligands involved in this process and will likely 
identify additional regulatory mechanisms that prevent Notch-induced extrathymic T cell 
development. 
 
 
1.1.6 T-Cell Development and Notch Signalling 
T lymphocytes are part of adaptive immune system that recognizes and eliminates specific 
foreign antigens. T lymphocytes arise in the bone marrow and migrates to the Thymus Gland 
to mature into CD4 or CD8 cells. Mature T cells express a unique antigen binding molecules, 
the T cell receptor (TCR) on their membrane, and can only recognize antigen that is bound to 
cell membrane protein called major histocompatibility complex (MHC) molecules. T cell that 
recognize self MHC molecules are selected for survival during positive selection [48]. 
However, T cells that react too strongly with self-MHC are eliminated through negative 
selection [48]. Maturation of T cells consists of six major steps (Figure 4). Thymocytes early 
in development lack detectable CD4 and CD8, and are referred to as double negative (DN). 
DN T Cells can be sub divided into 4 subsets (DN1-4) characterized by the presence or 
absence of cells surface molecules in addition to CD4 and CD8, such as CD44, an adhesion 
molecules, and CD25, the α chain of the IL-2 receptor. The cells that enter the thymus, DN1, 
are capable of giving rise to all subsets of T cells, and are phenotypically CD44
hi
 and CD 25
-
 . 
Once DN1 cells encounter the thymic environment, they begin to proliferate and express 
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CD25, becoming CD44
low
, and CD25
+
, they are called DN2 cells, where rearrangement of 
genes for the TCR chains begins . As cells progress to DN3 cells, the expression of CD44 is 
turned off and cells stop proliferating to start TCR β chain rearrangement. Upon its 
completion, the DN3 cells quickly progress to DN4 where the level of CD 25 decreases. Both 
CD4 and CD8 receptor are expressed in the Double positive (DP) stage, where rapid cell 
division increases the diversity of the T cells repertoire . After the rapid proliferation, TCRα, 
chain rearrangement starts , which is then followed by positive and negative selection . Cells 
that fail to make productive TCR gene arrangement or thymic selection are eliminated by 
apoptosis. The cells that survive will developed into immature Single Positive (SP) CD4 or 
CD8 thymocytes. These Single Positive thymocytes undergo additional negative selection and 
migrate to the medulla, where they pass from the thymus to the circulatory system. During the 
development of the T Lymphocytes, Notch expression and thus signaling  plays an important 
role. Notch1 expression is high in early DN thymocytes, low in DP cells, and intermediate in 
CD4 and CD8 SP cells [49]. Conversely, when compared to Notch1, Notch3 expression levels 
are significantly higher in DN and DP thymocytes (Figure 5 ), although they are specifically 
downregulated past the DN to DP transition and stay at very low to undetectable levels in 
mature T lymphocytes [50], [51]. Moreover, a significant role for Notch1 has been suggested 
in the initial T cell lineage commitment of bone marrow-derived common lymphoid 
precursors [52]. [53] and in intrathymic T cell lineage choices, by favoring the CD8 versus 
CD4 and 
αβ
 versus ᵞᵟ T cell lineage decision [54], [55], [56] as well as its requirement for a 
correct VDJκ rearrangement [57]. Conversely, a specific role of Notch3 at the pre-TCR 
checkpoint has been suggested. Indeed, Notch3 expression has been demonstrated to be 
preferentially upregulated by thymic stromal cell-derived signals in DN immature thymocytes 
prior to their transition to more mature DP cells and to be subsequently downregulated across 
the DN to DP transition [58]. 
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Figure 4 : Notch in T-Cell Development : Notch  signalling is required for commitment of a subset 
of double-negative 1 (DN1) cells to early thymocyte progenitors (ETPs) and for T-cell maturation up 
to the double-positive (DP) stage; the CD4 versus CD8 lineage commitment seems largely unaffected 
by Notch 1. T-cell precursors form in the bone marrow and migrate to the thymus to become double-
negative (DN) thymocytes. The Proliferation and differentiation of DN thymocytes occurs in the 
thymus. Rearrangement of T-cell receptor-  (TCRβ) genes (usually together with TCRG and TCRD 
genes) in such thymocytes is one of the first significant steps in differentiation. If rearrangement 
succeeds first, the cell is identified as a T-cell. If the TCRβ gene is rearranged first, the cell 
becomes an T-cell. - and -chain surrogates are then expressed on the cell surface together with 
CD4 and CD8, making the cell a double-positive thymocyte. In addition to the Delta-like 1 (DLL1) or 
DLL4–Notch-1 interactions (D1) that are required for T-cell development, the differentiation of late 
DN T-cell precursors to DP T-cell precursors also requires (pre-) TCR signalling. 
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1.1.7  Role of Notch signaling in Leukemogenesis 
The role of Notch in the development of leukemia was from the observation that in rare cases 
of human T cell acute lymphoblastic leukaemia (T-ALL), Notch1 was truncated by 
t(7;9)(q34;q34.3) chromosomal translocation, leading to the production of a dysregulated 
constitutively active N1
ICD
 [59]. Subsequently, several research groups have generated in 
vitro and in vivo experimental models, involving constitutively active Notch receptors or 
other components of its transduction pathway, in an attempt to understand the cellular and 
molecular events involved in the pathogenesis of the human disease. The different in vivo 
experimental systems were all based on a gain-of-function approach, in most cases using T 
cell-specific Lck promoter-dependent expression of the constitutively active N1
ICD
 or N3
ICD
, 
in transgenic mice [60] [61] [54] Alternatively, retroviral vector-driven N
ICD
 constructs were 
utilized to transduce bone marrow precursors, in order to reconstitute in lethally irradiated 
mice [62] [63]. The outcome of the different experimental systems appears to be quite 
different. Indeed, when experimental systems involving Notch1 are considered, it appears that 
mice injected with retrovirally-transduced bone marrow precursors develop a T cell leukemia 
with a significantly higher penetrance than Lck promoter N1
ICD
 transgenic mice, even when 
comparable Notch constructs were used [60] [61] [62] [63].  In this regard it is interesting to 
note that the retroviral-driven N1
ICD
 expressing bone marrow precursors have been shown to 
first repopulate the bone marrow (Days 22 postinjection) and later on the lymphoid organs, 
including the thymus, (after Day 40 postinjection) of irradiated recipient mice and between 
Days 65 and 110 all of the injected mice developed T cell leukemia [52]. Moreover, it was 
recently shown that N1
ICD
 transduced bone marrow precursors were not able to induce T cell 
leukaemic transformation in the absence of a functional pre-TCR [64] . Together, these 
observations suggest that the constitutive activation of Notch1 signalling in pre-thymic 
precursors is not sufficient to trigger the development of T cell leukemia before the transit in 
the thymus. A different oncogenic potential is observed when different N1
ICD
 constructs are 
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used to generate transgenic mice. Indeed, while transgenic mice carrying N1
ICD
 with an 
incomplete TAD only occasionally develop thymomas in older age [54], a low but significant 
percentage of N1
ICD
 transgenic mice carrying a complete TAD region develops T cell 
leukaemia [60]. The discrepancy between the 100% incidence of T cell leukaemia in mice 
injected with bone marrow precursors retrovirally transduced with N1
ICD
 and the occasional 
to low percentage of Lck- N1
ICD
 transgenic mice developing T cell leukaemia suggests that 
the main Notch1-dependent oncogenic event resides in the bone marrow, being possibly 
related to the ability of Notch1 to selectively induce the early T cell lineage commitment at 
the level of common lymphoid precursors [52]. In contrast to Lck-N1
ICD
 transgenic mice, 
Lck-N3
ICD
 transgenic mice, overexpressing a N3
ICD
 domain, that ordinarily lacks a TAD 
region, develop an aggressive T cell leukaemia, early in age [61], suggesting that the Notch3-
dependent oncogenic event takes place inside the thymus. Interestingly, lymphoma cells of 
Lck-N3
ICD
 transgenic mice retain the same phenotypic features as pre-leukaemic thymocytes 
(i.e. sustained expression of CD25 and pTα chain and a constitutively activated NFκB [61] . 
Ligand-independent pre-TCR signalling is known to result in NFκB activation, and may be 
responsible for anti-apoptotic and proliferation signals, thereby promoting neoplastic 
transformation. Therefore, the sustained expression of pTα observed in Lck-N3ICD transgenic 
mice could be responsible, at least in part, for the constitutive activation of NFκB, which 
mediates an anti-apoptotic response in leukaemic cells, suggesting possible relationships 
between constitutively activated survival and/or proliferation related transduction pathways 
and T cell neoplastic transformation.  
Pre and post-receptor conserved components of the Notch signalling pathway are also directly 
or indirectly involved in T cell leukemogenesis. Retroviral-mediated overexpression of the 
Notch ligand Dll4 in bone marrow cells induces T cell leukaemia [42]. As for post-receptor 
events, the DNA-binding protein RBPJκ (CBF1), after physical interaction with N1ICD, 
activates the transcription of target genes including the HES family of basic helix–loop–helix 
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(bHLH) transcription factors (reviewed in [65]. Among HES family members, HES-1 has 
been suggested to have a potential role in T cell leukemogenesis, because it is overexpressed 
in murine T lymphoma cells carrying a murine leukaemia provirus insertion in one of the 
Notch1 alleles, which leads to a constitutively active truncated Notch1 protein 
[66].Transcriptional activation of HES-1 has also been shown to correlate with 
leukaemogenesis induced in mice transplanted with bone marrow cells retrovirally transduced 
with Notch1 and in Notch3 transgenic mice. The expression of Deltex, is up-regulated in both 
N1
ICD
 and N3
ICD
 transgenic mice and was found at high levels in a number of murine 
thymomas.  
Together these results suggest a crucial role for HES1 and Deltex in mediating Notch activity 
in leukaemogenesis. However, enforced expression of each of them is not sufficient to induce 
leukaemia [49], suggesting that the leukaemogenic process needs the collaboration of 
different Notch-dependent transduction pathways. The generality of involvement of 
dysregulated Notch signalling in stemming from the above described experimental models, 
has been supported recently by its occurrence in spontaneous human T-ALL. Indeed, 
combined misexpression of Notch3, HES1 and Deltex has been described to be 
pathognomonic of T-ALL and to correlate with either remission or relapsing stages of the 
disease. A critical candidate check point for neoplastic transformation appears to be 
represented by the DN to DP transition, and is dependent on pre-TCR signalling since 
abrogation of pre-TCR signals prevents Notch3-induced leukaemogenesis [51]. Indeed, this 
step recapitulates a number of pro-survival and proliferation signals mainly represented by the 
activation of ligand-independent pre-TCR signalling and the subsequent activation of NFκB 
and inhibition of E2A activity, which are possibly related to each other. This step is also 
characterized by the transient up-regulation of Notch3, followed by its decreased expression 
in DP cells. Hampering the Notch3 down-regulated expression past the DN to DP transition, 
through transgenic expression of N3
ICD
, has been shown to be able to increase pTα expression 
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and NFκB activation, resulting in T cell leukaemia. Notch1 may share some of these features 
with Notch3. Indeed, up-regulation of pTα by Notch1 has been reported [60]. Moreover, 
Notch1 has been shown to control NFκB activity, although controversial results have been 
described. Indeed, Notch1, by binding to p50 subunit, displays both stimulatory and inhibitory 
activity upon NFκB-mediated transactivation. The constitutive activation of NFκB activity 
has been observed in both transiently transfected T cells with N3
ICD
 and thymocytes from 
Lck-N3
ICD
 transgenic mice. The leukemogenic potential of NFκB has been reported. Indeed, 
the development of aggressive T cell lymphoma/leukemia has been demonstrated in 
transgenic mice expressing v-Rel under the control of a T cell-specific promoter. NFκB has 
also been shown to be involved in HTLV1-induced lymphomagenesis via Tax induction of 
the degradation of IκBα, thereby activating NFκB. By different criteria, the Notch3-induced T 
cell malignancies strikingly resemble HTLV-1-associated T cell leukaemia [61]. A further 
mechanism leading to the leukemogenic process relates to the sustained downregulation of 
E2A activity as a consequence of dysregulated pre-TCR and/or Notch signalling. It is also 
worthwhile noting that the activity of E2A-encoded E47 and E12 transcription factors may be 
negatively regulated by the HLH transcription factors Tal-1, Tal-2 and Lyl-1, which are 
reported to be overexpressed or to harbour genetic abnormalities in human TALL. Indeed, 
Tal-1 transgenic mice develop T cell leukaemia. Finally, NFκB is strongly activated in 
thymocytes from Tal-1 transgenic mice, further supporting a relationship between T cell 
leukaemogenesis, activation of NFκB and inhibition of E2A activity.  
Together, these results suggest possible relationships between Notch receptors, HLH 
transcription factors and leukaemogenesis. Consistent with this hypothesis there is the 
observation that a constitutively active Notch1 accelerates the development of T cell tumours 
in E2A-PBX1 transgenic mice, suggesting a possible collaborative relationship between 
Notch signalling and the oncogenic fusion protein involving the E2A gene [67]. 
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Figure 5 : Schematic diagram of intrathymic T cell development. The sequence of developmental 
stages and the main signaling pathways involved are shown. DN, CD4
−
CD8
−
 double negative 
thymocytes; DP, CD4
+
CD8
+
 double positive thymocytes; SP, CD4
+
 and CD8
+
 thymocytes. The model 
illustrates the possible role of Notch3 in regulating pre-TCR checkpoint and its interaction with main 
survival/proliferation-triggering signals (E2A, pre-TCR, NFκB) 
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1.2 microRNAs 
1.2.1 General 
Cells contain a variety of non coding RNAs, including components of the machinery of gene 
expression, such as tRNAs and rRNAs, and regulatory RNAs that influence the expression of 
other genes [68]. It has become increasingly apparent that non coding RNAs are impressively 
diverse, and that a significant fraction of the genes of all organisms do not encode proteins. 
One of the small noncoding RNAs - the microRNAs (miRNAs) has been recognized when in 
1993 the regulation of gene regulation of the gene lin-14 by a small RNA, lin-4, was reported 
in Caenorhabditis elegans [69]. It was not until seven years later that a second small RNA, 
let-7, was identified
 
[70]. Since then, miRNAs have been discovered in virtually all plant and 
animal species, and their biological functions and mechanisms of action have become subjects 
of intense research. miRNAs are small , evolutionary conserved non-coding RNAs of 18-25 
nucleotides in length, that are often encoded in clusters in the genome. Members of miRNA 
families have homologous sequences, but are not necessarily transcribed from the same 
genomic region. However, there are many cases in which miRNA families are found in 
clusters and their transcription is co-regulated. According to the latest version of the miRNA 
database miRBase,  released in August 2012, approximately 2,042 mature miRNAs have been 
experimentally identified so far in human, and approximately 1,281 in mouse
 
[71]. 
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2.2 Biogenesis of miRNAs 
Early annotation of the genomic position of miRNAs indicated that most miRNAs are located 
in the intergenic regions ( >1 kb away from the annotated / predictaded genes), although a 
sizeable minority was found in the intronic regions of known genes in the sense or antisense 
orientation (Figure 6) [72] [73]. Thus most miRNA genes are transcribed as autonomous 
transcription units. Another interesting observation was that these clustered miRNAs might be 
transcribed from a single polycistronic transcription unit. miRNA genes encoded in the 
genome are transcribed  into long primary miRNAs (pri-miRNAs) by RNA polymerase II or, 
in some cases, by RNA polymerase III. [74] [75] [76]. Typically, animal pri-miRNAs display 
a 33 bp stem and a terminal loop structure with flanking segments[77]. Many pri-miRNAs 
originate from clusters; loci of miRNAs positioned closely together. Primary miRNA 
processing begins in the nucleus where an RNase III enzyme, Drosha, removes the flanking 
segments and a 11 bp stem region, thereby catalyzing conversion of pri-miRNAs into 
precursor miRNAs (pre-miRNAs) [74] [78]. Pre-miRNAs are generally 60–70 nt long hairpin 
RNAs with 2-nt overhangs at the 3’ end. Drosha typically acts together with the DiGeorge 
syndrome critical region 8 protein (DGCR8) for efficiency and precision [79] [80] [81]. 
However, a Drosha ⁄ DGCR8- independent processing pathway can also produce pre-
miRNAs. In this pathway, the nuclear splicing machinery provides pre-miRNA from introns. 
miRNAs produced by this pathway are appropriately called mirtrons [82] [83]. Mirtrons 
encompass a small group of miRNAs but are found in many organisms. Pre-miRNAs are 
exported from the nucleus to the cytoplasm by the exportin-5 ⁄ RanGTP heterocomplex ([84] 
[85] [86] and processed by RNase III enzyme Dicer [87]. Dicer is thought to act with dsRBDs 
containing partner proteins HIV TAR RNA-binding protein (TRBP) [88] [89] and ⁄ or PKR 
activating protein (PACT) [89] [90]. Dicer cleaves pre-miRNAs into 21–25 nt long miRNA⁄ 
miRNA* duplexes, each strand of which bears 5’ monophosphate, 3’ hydroxyl group and a 3’ 
2-nt overhang. Of a miRNA⁄ miRNA* duplex, only one strand, designated the miRNA strand, 
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is selected as the guide of mature RISC, whereas the other strand, the miRNA* strand, is 
discarded during RISC assembly. Such biased strand selection depends on the balance of at 
least three properties of a miRNA⁄miRNA* duplex: i) the structure; ii) the 5’ nucleotide 
identity; and iii) the thermodynamic asymmetry [91]. The core component of RISC is a 
member of Argonaute (Ago) subfamily proteins, of which there are four paralogs (Ago1–4) in 
humans. RISC assembly follows a multi-step pathway. The first well-characterized event of 
RISC assembly is RISC loading. During RISC loading, miRNA⁄miRNA* duplexes are 
incorporated into Ago proteins. Ago1–4 disfavor duplexes bearing only non-central 
mismatches, but can incorporate siRNA-like perfectly complementary duplexes. RISC 
loading is not a simple binding of miRNA⁄miRNA* duplexes and Ago proteins, but rather an 
ATP-dependent active process [92]. Structural analyses of Thermus thermophilus Ago protein 
suggest that a generic miRNA⁄ miRNA* duplex is too bulky to fit directly [93]. To enable 
loading, drastic conformational opening of Ago protein appears necessary; an energetic 
reaction likely powered by ATP hydrolysis [91]. Recently it was reported that Hsc70 ⁄ Hsp90 
chaperone machinery mediates such conformational opening [94]. After RISC loading, the 
duplex is unwound and the miRNA* strand is discarded from Ago protein. Surprisingly, 
unwinding does not require ATP; presumably unwinding is linked to the release of the 
structural opening incurred upon Ago proteins during RISC loading [91]. Unwinding can be 
further classified into slicer-dependent unwinding and slicer independent unwinding. In 
humans, only Ago2 retains the cleavage activity [95] and thus can facilitate unwinding by 
slicing the miRNA* strand [92] [96]. However, passenger strand cleavage occurs only if the 
duplex is extensively base-paired, especially around position 10–11 of the guide. Most 
miRNA⁄ miRNA* duplexes bear central mismatches and are therefore unwound by a slicer-
independent mechanism. Mismatches in the seed region (guide position 2–8) and ⁄ or the 
middle of the 3’ region (guide position 12–16) greatly enhance the unwinding efficiency in all 
four Ago proteins [92]. 
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MicroRNA target sites often lie in the 3’ untranslated region (UTR) rather than in the 5’ UTR 
or ORF, probably because translation (i.e. movement of ribosomes) will counteract RISC 
binding[97] [98]. Typically, a target mRNA bears multiple binding sites of the same miRNA 
(e.g. let-7 and HMGA2) [99] and ⁄ or several different miRNAs (e.g. miR-375, miR-124, and 
let-7b and Mtpn) [100]. Importantly, not all nucleotides of a miRNA contribute equally to 
RISC target recognition. This target recognition is largely determined by base-pairing of 
nucleotides in the seed region and is enhanced by additional base-pairing in the middle of the 
3’ region. [97] [100] [101] [102]. How RISC acts upon target mRNA is determined by both 
the character of the Ago protein in which the miRNA is incorporated and complementarity 
between the miRNA strand and the target mRNA. Ago2 is capable of RNA cleavage,( Liu J 
[95], Science 2004; 305: 1437–41) but this reaction requires extensive base-pairing between 
the miRNA strand and mRNA target. Some miRNAs silence target mRNAs through cleavage, 
just as siRNAs do. [103] In contrast to this example, the complementarity between the 
miRNA strand and target mRNA is typically limited, [97] [100] [101] [102] which renders 
RISC incapable of target cleavage. In such a case, Ago protein provides a platform to recruit 
factors, including GW182 proteins (TNRC6A–C in humans), required for translational 
repression and mRNA deadenylation ⁄ degradation of target mRNAs. Such slicer independent 
silencing can be reconstituted by artificial tethering of an Ago protein or a GW182 protein to 
an mRNA, independent of the presence of a miRNA [104] [105]. This contrasts with target 
mRNA cleavage, where the presence of a guiding small RNA is a de facto requirement. 
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 Mechanism of Translation repression:- 
At least six models of translational repression have been proposed : 
i) RISC induces deadenylation which causes decrease of translational efficiency by 
blocking target mRNA circularization; [106] [107] [108]. 
ii) RISC blocks cap function by interacting with either the cap or eIF4E; [109] [110] 
[111] [112] [113].  
iii) RISC blocks a late step in initiation of translation such as recruitment of 60S 
ribosomal subunit[114] 
iv) RISC blocks a post-initiation step such as elongation and ⁄ or ribosome dropoff 
[115] 
v) RISC induces proteolysis of nascent peptides during translation [116].  
vi) RISC recruits target mRNAs to processing bodies, in which mRNA is degraded 
and ⁄ or stored in a translationally inactive state [117] [118]. 
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Figure 6 : MicroRNA (miRNA) genomic organization, biogenesis and function. Genomic 
distribution of miRNA genes. The sequence encoding miRNA is shown in red. TF: transcription 
factor. (A) Clusters throughout the genome transcribed as polycistronic primary transcripts and 
subsequently cleaved into multiple miRNAs; (B) intergenic regions transcribed as independent 
transcriptional units; (C) intronic sequences (in grey) of protein-coding or -non-coding transcription 
units or exonic sequences (black cylinders) of non-coding genes. Primary miRNAs (pri-miRNAs) are 
transcribed and transiently receive a 7-methylguanosine (
7m
GpppG) cap and a poly(A) tail. The pri-
miRNA is processed into a precursor miRNA (pre-miRNA) stem-loop of ∼60 nucleotides (nt) in 
length by the nuclear RNase III enzyme Drosha and its partner DiGeorge syndrome critical region 
gene 8 (DGCR8). Exportin-5 actively transports pre-miRNA into the cytosol, where it is processed by 
the Dicer RNaseIII enzyme, together with its partner TAR (HIV) RNA binding protein (TRBP), into 
mature, 22 nt-long double strand miRNAs. The RNA strand (in red) is recruited as a single-stranded 
molecule into the RNA-induced silencing (RISC) effector complex and assembled through processes 
that are dependent on Dicer and other double strand RNA binding domain proteins, as well as on 
members of the Argonaute family. Mature miRNAs then guide the RISC complex to the 3′ 
untranslated regions (3′-UTR) of the complementary messenger RNA (mRNA) targets and repress 
their expression by several mechanisms: repression of mRNA translation, destabilization of mRNA 
transcripts through cleavage, de-adenylation, and localization in the processing body (P-body), where 
the miRNA-targeted mRNA can be sequestered from the translational machinery and degraded or 
stored for subsequent use. Nuclear localization of mature miRNAs has been described as a novel 
mechanism of action for miRNAs. Scissors indicate the cleavage on pri-miRNA or mRNA. 
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1.2.3 miRNAs in Haematopoiesis. 
Haematopoietic stem cells (HSCs) reside mainly in the bone marrow and give rise to all blood 
cell lineages, including cells that constitute the immune system [119]. HSCs must maintain a 
precise balance between self renewal and differentiation into multipotent progenitors, which 
subsequently give rise to both the lymphoid and myeloid branches of the haematopoietic 
system. Thus, Hematopoiesis represents an elegant developmental model to observe normal 
changes in miRNAs expression and to test the effects of miRNA levels on differentiation and 
tumorigenesis. Although miRNAs have been studied in other stem cell types, such as 
embryonic stem cells, there are currently limited data on the role of miRNAs in HSCs [120]. 
Several groups have carried out global miRNAs expression profiling of human CD34
+
 stem 
and progenitor cells and have identified certain miRNAs expressed by this cell population 
[121] [122]. Mice deficient in ARS2, which contributes to pri-miRNA processing, have bone 
marrow failure possibly owing to defective HSC function [123]. These studies provide initial 
evidence that the miRNA pathway is important in HSC function.  
Individual miRNAs have also been implicated in HSC biology. Homeobox (HOX) genes have 
important roles in regulating HSC homeostasis, and miRNAs from the miR-196 and miR-10 
families were found to be located in the HOX loci; both could directly repress HOX family 
expression [124] [125] [126] [103] [127] [128]. miR-196b is expressed specifically in mouse 
short-term HSCs, regulated by the HSC transcription factor family mixed lineage leukaemia 
(Mll), and has a functional role in modulating HSC homeostasis and lineage commitment, 
possibly through the regulation of expression of certain HOX genes33. miR-126 has also been 
shown to regulate expression of HOXA9 [128] and the tumour suppressor polo-like kinase 2 
(PlK2) [129], through which miR-126 is thought to mediate its biological effects. Functional 
studies of bone marrow progenitors showed that miR-126 increased colony formation in vitro, 
suggesting that it may promote the production of downstream progenitors by HSCs [129]. 
miR-221 and miR-222 were also shown to inhibit KIT expression in stem and progenitor 
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cells, leading to impaired cell proliferation and engraftment potential [130]. Although these 
studies suggest a role for specific miRNAs in HSC biology, additional work is needed to 
directly assess the influence of these and other miRNAs on the function of carefully sorted 
HSC populations regarding long-term, multilineage engraftment in vivo. 
 
Figure 7: miRNA-mediated regulation of early haematopoietic cell development. miRNA 
pathway, which involves arsenate resistance protein 2 (ARS2), has a general role in haematopoietic 
stem cell (HSC) engraftment, which probably influences the reconstitution potential of long-term 
HSCs (LT-HSCs). Individual miRNAs have been shown to repress the expression of HSC-relevant 
genes and affect the production of haematopoietic progenitor and lineage-positive cells. Potential 
points of miRNA function during early haematopoiesis are indicated. miR-221 or miR-222 regulate 
KIT expression, which is thought to affect stem cell homeostasis. miR-196b is specifically expressed 
by short-term HSCs (ST-HSCs) and regulates mRNAs encoding the homeobox (Hox) family, in 
cooperation with miR-10 family members. The expression of miR-10 family members by HSCs is not 
as clearly defined. miR-126 represses the mRNAs encoding polo like kinase 2 (PLK2) and HoxA9, 
and has been shown to promote expansion of progenitor cells. CLP, common lymphoid progenitor; 
CMP, common myeloid progenitor; MPP, multipotent progenitor. 
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1.2.4 miRNAs functions in T Cells Development  
Similar to the development of innate immune cells, the development of T cells in the thymus 
and their activation in the periphery are also controlled by complex protein signalling 
networks that are subjected to regulation by miRNAs. Expression profiling of T cells has 
identified a broad range of expressed miRNA species and found that the expression patterns 
vary between T cell subsets and stages of development [131] [132] [133]. Adding to this 
complexity, several variants of a given miRNAs species can be found in T cells, with the 
mature miRNAs varying in length at either the 3ʹ or 5ʹ end or containing mutated sequences 
[133]. Furthermore, proliferating T cells express genes with shorter 3ʹ UTRs than those in 
resting T cells [134], rendering these mRNAs less susceptible to regulation by miRNAs 
owing to the loss of miRNA binding sites. These findings suggest that miRNA-mediated 
regulation of mRNA targets in T cells, and probably other immune cells, is a dynamic process 
that is influenced by a broad range of factors. T cell-specific deletion of Dicer has revealed a 
requirement for the miRNA pathway in the development of mature T cells, as the total 
numbers of which are lower in the mutant mice than wild-type mice [135] [136]. To date,  two 
specific miRNAs have been implicated in T cell development, and probably account for some 
of the phenotype of Dicer deficiency in T cells. The miR-17–92 cluster impairs the expression 
of mRNAs encoding pro-apoptotic proteins, including BCl-2-interacting mediator of cell 
death (BIM; also known as BCl2l11) and phosphatase and tensin homologue (PTEN). This 
miRNA cluster is thought to increase T cell survival during development and is expressed 
during the  DN2 stage of thymopoiesis [137]. Furthermore, the strength of TCR signaling 
influences whether thymocytes are positively or negatively selected during thymic 
development, and specific miRNAs have been implicated in this process. miR-181a, which is 
increased during early T cell development, enhances TCR signalling strength by directly 
targeting a group of protein phosphatases, including dual specificity protein phosphatase 5 
(DUSP5), DUSP6, SH2-domain-containing protein tyrosine phosphatase 2 (SHP2; also 
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known as PTPN11) and protein tyrosine phosphatase, non-receptor type 22 (PTPN22) [138]. 
Recent data have also indicated a role for miRNAs in the differentiation of T cells into 
distinct effector T helper cell subsets. This is best exemplified by mice deficient in miR-155, 
in which T cells are biased towards T helper 2 (TH2)-cell differentiation, indicating that miR-
155 promotes differentiation into TH1 cells [139]. Certain miRNAs, such as the miR-17–92 
cluster, might also be involved in the development and function of T follicular helper (TfH) 
cells, which are specialized T cells that are dedicated to supporting B cells in germinal centres 
and facilitating antibody affinity maturation and class switching [140] [141]. TH17 cells have 
been identified as important mediators of inflammatory disease. A recent study found that 
miR-326 promotes TH17 cell development both in vitro and in vivo by targeting [142]. The 
generation of mice with a conditional deletion of Dicer or Drosha in regulatory T (TReg) 
cells has shown a requirement for the miRNA pathway in forkhead box P3 (fOXP3)+ TReg 
cells. [143] [144]. These mice develop a lethal autoimmune inflammatory disease, consistent 
with impaired development or function of TReg cells. Specifically, it was shown that miR-
155 is important for TReg cell homeostasis and overall survival, and this is thought to involve 
the direct targeting of Socs1 [145]. However, because the absence of miR-155 did not 
reproduce the severe disease that occurs in mice with a conditional deletion of Dicer, 
additional miRNAs are probably involved in TReg cell biology. Of note, the expression of 
miR-142-3p was recently shown to be repressed by FOXP3, leading to increased production 
of cyclic AMP and suppressor function of TReg cells [146]. Several other miRNAs are 
expressed by TReg cells and await functional assessment [147]. 
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A) miRNAs in T-Cell Development Development 
 
 
 
B) miRNAs in T-Cell Function 
 
Figure 8 : miRNA-mediated regulation of T cell development and function. A) The production of 
miRNAs by Dicer is required for efficient T cell development in vivo. T cells go through a stepwise 
developmental programme in the thymus. During this process, T cell survival and selection is 
influenced by the miR-17–92 cluster (which targets the mRNAs encoding BCL-2 interacting mediator 
of cell death (BIM), and phosphatase and tensin homologue (PTEN)) and miR 181a (which targets 
mRNAs encoding several phosphatases, including dual-specificity protein phosphatase 5 (DUSP5), 
DUSP6, SH2-domain-containing protein tyrosine phosphatase 2 (SHP2) and protein tyrosine 
phosphatase, non-receptor type 22 (PTPN22)). B)  In the periphery, mature T cell differentiation is 
modulated by miRNAs, including miR-155, which promotes skewing towards T helper 1 (TH1) cells 
through macrophage-activating factor (MAF) repression, and miR-326, which promotes skewing 
towards TH17 cells by targeting the mRNA encoding ETS1. Regulatory T (TReg) cells also depend on 
miRNAs to maintain immune tolerance to self tissues, thereby preventing autoimmunity. miR-155 
repression of suppressor of cytokine signalling 1 (SoCS1) expression has been implicated in TReg cell 
survival. CLP, common lymphoid progenitor; DN, double negative; DP, double positive; FoxP3, 
forkhead box P3; SP, single positive. 
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1.2.5 Notch and miRNAs 
miRNAs play critical roles in Notch signaling pathway. Several miRNAs have been shown to 
cross-talk with Notch pathway. However, the role of miRNAs in the Notch pathway remains 
unclear.  
miR-1 belongs to tumor suppressor group which are generally  down-regulated in cancer such 
as primary human hepatocellular carcinoma (HCC), prostate cancer, head and neck, and lung 
cancerS. [148] [149] [150] [151] [152]. Ectopic expression of miR-1 has been shown to 
downmodulate these tumours by downregulating its target genes exportin-6 and protein 
tyrosine kinase 9 [148] MET, Pim-1, FoxP1, and HDAC-4. Recently, it has been reported that 
miR-1 regulates Notch signaling pathway by directly targeting the Notch ligand Delta-1 (Dll-
1) in Drosophila (Figure 9) [153]. It has also been found that Dll-1 protein levels are 
negatively regulated by miR-1 in mouse embryonic stem cells [154]. These results suggest 
that miR-1 could regulate the Notch signaling pathway; however further in-depth research is 
needed in order to fully understanding how miR-1 regulate the Notch pathway.  
miR-34, which has been found to participate in p53 and Notch pathways regulation is 
consistent with its tumor suppressor activity [155]. The expression of miR-34a was reported 
to be lower or undetectable in pancreatic cancer, osteosarcoma, breast cancer and non-small 
cell lung cancer [156] [157] [158], and also the inactivation of miR-34a was identified in cell 
lines derived from some tumors including lung, breast, colon, kidney, bladder, pancreas and 
melanoma [159]. miR-34a overexpression in glioma cells down-regulated the protein level of 
Notch-1, Notch-2, and CDK6 [160]. Moreover miR-34 restoration in human gastric cancer 
cells reduced the expression of target gene Notch  and down-regulated Notch1 and Notch2 in 
the pancreatic cancer cells [161] [155]. Consistently, pancreatic cancer stem cells which are 
enriched with  tumor-initiating cells or cancer stem cells show high levels of Notch-1/2 and 
loss of miR-34. Thus, these evidence suggest that miR-34 may be involved in pancreatic 
cancer stem cell self-renewal, potentially via the direct modulation Notch signaling[155]. 
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The miR-146 was previously reported to function as novel negative regulators that help to 
fine-tune the immune response. It has been demonstrated a decrease in miR-146b in adult T-
cell Leukemia cells. The decrease in miR-146b may lead to increased inflammation and 
decreased TReg functions, resulting in leukemia [162]. Transduction of miR-146a or miR-
146b into breast cancer cells i) decreased the expression of epidermal growth factor receptor 
ii) down-regulated NFκB activity iii) inhibited migration and invasion in vitro and iv) 
suppressed lung metastasis in experimental xenograft models [163] [164]. Interesting, miR-
146a in C2C12 cells was found to regulate Numb [165], which is known to induce the 
ubiquitin mediated Notch protein degradation. Indeed, Notch activation and the loss of Numb 
expression were found in a large proportion of breast [166] [167]. It has been reported that 
over-expression of Notch1 stimulates NFκB activity in several cancer cell lines [168] and 
since miR-146 also regulate NFκB activity, it clearly suggest that miR-146 could regulate 
NFκB through Notch mediated signaling pathway. However, the role of miR-146 in Notch 
signaling pathway need further innovative investigations. 
miR-199a was observed to be down-modulated in ovarian cancer [169], and in hepatocellular 
cancer. Moreover, it was found that over expression of miR- 199a can introduce cell cycle 
arrest in G2/M phase [170]. Very recently, miR- 199b-5p was seen to be a regulator of the 
Notch pathway targeting the transcription factor Hes-1, thus negatively regulating the 
Medulloblastoma (MB) tumors cell growth. Moreover, over-expression of miR-199b-5p 
decreased the MB stem-like cells (CD133
+
) and also blocked expression of several cancer 
stem-cell genes. Further, the expression of miR-199b-5p in the non-metastatic cases was 
significantly higher than in the metastatic cases. The patients with high levels of miR-199b 
expression showed a better overall survival [171]. These results clearly suggest that miR-199 
family could be very important in the regulation of multiple signaling pathways including 
Notch, and thus further in-depth studies are needed in order to clarify the biological 
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significance and mechanisms on how miR-199 can regulate the Notch signaling pathway in 
human cancers. 
The miR-200c was down-regulated in benign or malignant hepatocellular tumors [172]. miR-
200 family regulates epithelial–mesenchymal transition (EMT) by targeting zinc-finger E-box 
binding homeobox 1 (ZEB1) and [173] [174] [175] [176]. miR-200 family regulates the 
expression of ZEB1, Slug, E-cadherin, and vimentin, and thus the re-expression of miR-200 
could be useful for the reversal of EMT phenotype to mesenchymal- to-epithelial transition 
[177].  It has been found that the expression of both mRNA and protein levels of Notch1 to -
4, Dll-1, Dll-3, Dll-4, Jagged-2 as well as Notch downstream  targets, such as Hes and Hey, 
were significantly higher in PC3 PDGF-D cells (unpublished data). Importantly, Notch-1 
could be one of miR-200b targets, because over-expression of miR-200b significantly 
inhibited Notch-1 expression (unpublished data). 
Recently, miR-451 and miR-709, were suggested as potent tumor suppressors in Notch1-
induced mouse T-ALL which expressions are progressively down-regulated during T-ALL 
transformation from benign polyclonal cells to malignant monoclonal cell and when co-
expressed in a Notch1-induced model of TALL induce the block of the tumor cell growth. 
[178]. Forced expression of miR-150 reduces Notch3 levels in T-cell lines and has adverse 
effects on their proliferation and survival suggesting that control of the Notch pathway 
through miR-150 may have an important impact on T-cell development and physiology [179]. 
Also miR- 206 was shown as a pro-apoptotic activator of cell death, which was associated 
with its inhibition of Notch3 signaling and tumor formation [180]. Although, certain miRNAs 
have been established clear to regulate Notch pathway in both development and progression 
in different malignancies [181], the cross-talk between miRNAs and Notch pathway in T-
ALL remains to be better elucidate. 
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Figure 9 :  Diagrammatic representation of involvement of miRNAs in regulating Notch 
Signalling Pathway 
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2. Aim of the Work 
Despite the considerable progress in the study of the miRNAs biology and their role in 
various diseases and in human tumors [182] [183] it is still not fully understood the 
mechanism and signalling involved in the regulation of their expression in different contexts. 
In the last few years, it has been demonstrated that the miRNA pathway plays a critical roles 
in the Notch signaling [181] [184] [178], and a growing number of works revealed Notch as 
post-transcriptional target of several miRNAs  [185] [186] [187] [179] [180], suggesting that 
the study of the cross talk between the two pathways may be a new point of view to better 
understand the biology and the causes of tumors associated with Notch deregulation, such as 
T-ALL leukaemia. In this regard, it was demonstrated that in a mouse model of T-ALL the 
constitutively activation of Notch1 induces the repression of miR-451 expression that acts as 
tumor suppressor in T cell leukemogenesis. [178]. Recently, the comparison of microarray 
miRNA profiling of GSI treated versus the vehicle alone treated T-ALL cell lines suggested 
that Notch1 signaling repress the expression of miR-223 and, on the other hand, a different 
study  identified miR-223 as one of five onco-miRNAs that accelerates leukemogenesis in a 
Notch1-driven mouse T-ALL model [188]. Given the oncogenic role of Notch3 in T-ALL 
[61] [51] and that the activation of its signaling was linked to the regulation of the 
transcription of different genes [51] [189] [190], in this work, we evaluated  the set of 
miRNAs which are regulated by the activation of Notch3 signaling and that cooperate to its  
oncogenic activity in T-ALL leukemia context. 
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3) Materials and Methods :  
 
 
3.1) Mice 
 
The generation and typing of N3
IC
 tg mice have been described (Bellavia et al., 2000). The 
studies involving animals have been conducted following the Italian National Guidelines for 
Animal Care established in Decree number 116 of 27 January 1992, in accord to the directive 
CEE 86/609, as well as in Circular number 8 of the Italian Ministry of Health, 23 April 1994. 
 
3.2) Cell Lines  
Jurkat cell lines were purchased from (DSMZ) , Jurkat stably deleted for IKKᵞ were obtained 
from Prof Tuosto L, and Molt3 cell lines were kindly provided by Prof Indraccolo S. Human 
T-lymphoblastic cell lines JURKAT, Jurkat IKKᵞ-/- & Molt3 were kept in culture in RPMI 
1640 (Gibco) supplemented with 10% FBS (Gibco) and 1 mmol/L L-glutamine at 37°C in 5% 
CO2. HEK 293T & M31cells lines were kept in culture in D-MEM (Gibco) supplemented 
with 10% FBS (Gibco) and 1 mmol/L L-glutamine at 37°C in 5% CO2. 
 
3.3) Antibodies, Drugs and Treatments  
Primary antibodies used for Western Blot : Notch3 #2889 (Cell Signalling), c-Myc – (9E10)-
SC-40, Cleaved Notch1(Val1744) #4147 (Cell Signalling), p-p65(Ser536) (93H1) #3033 
(Cell Signalling), IkBα - #9242 (Cell Signalling), NFκB(p65) – (H-286) sc-7151, Cyclin E 
(HE12) sc-247, Aurora A/AIK (IG4) #4718 (Cell Signalling), FBxw7 – (H-300) sc-33196, β-
actin (C4) sc-47778, Notch1 (C-20) sc-6014-R, α-tubulin (TU-02) sc-803, Primary antibodies 
used for ChIP assays : NFκB(p65) (relA) Cat # 17-10060 (Milipore), ChIP Anti-RBPJK 
antibody  Cat – ab25949 (Abcam). Whenever required, ᵞ-secretase inhibitor IX (GSI) (Cat nos 
565770) (Calbiochem) was added at the concentration of 10µM to the growth medium of 
human T-lymphoblastic cell lines JURKAT and MOLT3 for mentioned time. 12-O-
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tetradecanoyl phorbol-13-acetate (TPA) P-8139 (Sigma) were used at 50ng/ml wherever 
required. BAY 11-7082 ( Calbiochem) was used at concentration of 10 nM. 
 
3.4) RNA isolation 
RNA was isolated from cells using Trizol (Invitrogen) or TriReagent (Ambion) according to 
the manufacturer’s instructions. In briefly,  TRIzol or TRIreagent was added to each sample 
and incubated at room temperature for 5 min, then 200 μl of chloroform per ml of TRIzol ( 
100 ul of 1-Bromo-3-Chloropropane (BCP) per ml of TRIreagent ) was added to each sample. 
The samples were then vortexed for 30 sec, incubated for a further 5-10 mins. Samples were 
then centrifuged at 13,000 x g for 15 min at 4°C. The upper aqueous phase was carefully 
removed and equal volume of Isopropyl alcohol was added and vortex for 30 sec, incubated 
for 10 mins at Room Temperature. The sample was centrifuged at 13000 RPM for 15 mins. 
The supernatant was discarded out and 1 ml of 70% ethanol was added. The sample was 
centrifuged at 8000RPM for 5 mins. Supernatant was discarded. The samples were dried and 
RNA was re-suspended in RNase Free water. 
 
3.5) RT-PCR 
The mRNA were reverse transcribed using Superscript II reagents (Invitrogen). In briefly, 
oligo-dT, dNTP (1mM) were added to mRNA to be reverse transcribed,  heated for 5 mins at 
65°CcDNA, followed by incubation on ice for 1 mins. Then 5X first strand buffer, 0.1M DTT 
and RNase were added , mixed and incubated for 2 mins at 42°C. Superscript II  Reverse 
transcriptase was added and incubated at 42°C for 60 mins. The reaction was inactivated by 
incubating at 70°C for 15 mins. 20 ng of the products were subjected to RT-PCR . Results 
were analyzed using the ΔΔCt method with normalization against β-Actin expression for 
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mRNA, respectively. The primer used for RT-PCR were bought from Applied Biosystem and their 
codes are as follows: 
Human 
 
Mouse 
Notch1 Hs01062014_m1 
 
Notch1 Mm00435249_m1 
Notch 3 Hs00166432_m1 
 
Notch 3 Mm00435270_m1 
Hes1 Hs00172878_m1 
 
Hes1 Mm01342805_m1 
cMyc Hs00905030_m1 
 
cMyc Mm00487803_m1 
B-actin Hs99999903_m1 
 
pTα Mm00478361_m1 
Tubulin Hs00258236_m1 
 
B-actin Mm00607939_s1 
 
 
3.6) miRNA profiling by Megaplex quantitative real-time PCR. 
The expression of genomic miRNAs in cells were profiled using stem–loop RT–PCR based 
384 well Taqman Low-density Array (TLDA) cards (Applied Biosystems). Briefly, for 
megaplex RT reaction, five hundred nanograms of total RNA was reversed transcribed, using 
multiplexed specific looped miRNA primers for pool A & B ( both human and mouse). The 
thermal-cycling condition used were : 40 cycles consisting of incubation at 16°C for 2 mins, 
42°C for 1 min, 50°C for 1 sec, then incubation for 5 mins at 85°C and hold at 4°C. The 
product of the megaplex reaction was mixed with TaqMan Universal PCR Master Mix, No 
AmpErase UNG, 2X. Then, 100 µl of the reaction mix were dispensed into each port of 
TaqMan MicroRNA Array (TLDA). Then, it was centrifuged and sealed, and were  subjected 
to the microfluidic RT-PCR technology which was performed by 7900HT System,  Applied 
Biosystems (Foster City, CA, USA).  
 
3.7) Analysis of TLDA data 
Raw data files from TLDA obtained from mice samples were processed using RealTime 
StatMiner™ v3 software (Integromics™ SL, Spain) . The normalization was done using mouse  
snoU6. The statistical analysis for the regulated miRNA was carried out with Mann-Whitney 
(Wilcoxon) Test. For the raw data which were obtained from M31, Jurkat, Molt3 samples, RQ 
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Manager Software were used which calculates the Cycle Threshold (Ct). The default value of 
0.2 was used. The miRNA which were having the Ct value of more that 35 was deleted 
manually.. Normalization of the Ct values in each sample was done with U6 snRNA control: 
[deltaCt = Ct(miR) – Ct (U6 snRNA)]. The fold-change for each miRNA probe was 
calculated : Fold change = 2 ^ -((meanDeltaCt(experimental) – meanDeltaCt(control)). The 
heat map was generated using Spotfire Software.  
 
3.8) Individual miRNA RT-PCR 
Individual Taqman miRNA assays (Applied Biosystems) were performed according to 
manufacturer’s instructions. Briefly, 5 μl of total RNA (10ng) isolated from cells was 
converted to cDNA using the microRNA reverse transcriptase Kit (Applied Biosystems) with 
3 μl of specific miRNA assay RT primer in a reaction volume of 15 μl. 1.33 μl of cDNA was 
used with 10 μl of Taqman Gene Expression Mastermix in a final volume of 20 μl . Plates 
were then run on a StepOnePlus qRT-PCR instrument (Applied Biosystems) using the 
manufacturer’s recommended cycling conditions: 50°C for 2 min, 95°C for 10 min followed 
by 40 cycles of 95°C for 15 s and 60°C for 1 min, with data collection at the end of each 
cycle. Ct values > 35 were below detection limit and excluded. Data was analysed by the 
ΔΔCt method and U6 snRNA (Code nos - 001973) was used to normalize the expression 
levels of miRNAs. Specific Taqman miRNA used in this study was miR-223 (Code Nos – 
002295).  
 
 
3.9) Plasmids 
 
Expression vectors used were as follows: Flag- N3
ICD
 (Palermo et al., 2012), HA- N3
ICD
 
(Bellavia et al., 2000), RBPJk and N1
ICD
  was kindly provided by Prof. Talora. MAM 
(Bellavia et al., 2007) were previously described. p65 & IκBα-sr  was kindly provided by 
Prof. Enrico De Smaele;  CEBPα (provided by Prof Gianluca Canettieri). 
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3.10) Cell transfections  
Trasfection of the HEK 293T and M31 cell line was performed using the lipofectamine 2000 
kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Transient 
transfection efficiency in M31, as assessed by expression of a GFP expression vector added in 
trace amounts, was ∼70 respectively. For Luciferase assay Renilla luciferase reporter vector 
pSV40-Renilla (5 ng) was also incorporated into each transfection (Promega, Madison, WI, 
USA) for normalization. The total amount of transfected DNA was kept constant by adding 
empty vector. At 36 h post-transfection, the cells were lysed in a reporter lysis buffer (Passive 
Lysis Buffer; Promega, Madison, WI, USA) at 100 μl/well. Firefly and pSV40-Renilla 
derived luciferase activities were measured in each sample with the Dual luciferase Assay 
System (Promega, Madison, WI, USA) using a Model TD-20/30 luminometer (Turner 
Designs). Light emission was measured for 10 s after injection. The specific luciferase 
activity of different transfections was determined in triplicate samples and was normalized on 
the Renilla luciferase activity. Data were expressed as means±s.d. of at least three 
independent experiments. Luciferase and renilla activity were assayed with a dual-luciferase 
assay system (Promega). Transient transfection of Jurkat cell lines with siNotch3 ( Code – sc-
37135) and its negative control (Code nos – AM4611), was carried out with Amaxa 
Nucleofection (Lonza) 
 
3.11) miRNA transfection 
 
Jurkat T-ALL cell lines were transiently transfected with 10 µM Control ( CN-001000-01-05 ) 
or Mimic ( C-300580-07-0005 ) of hsa-miR-223 or 10 µM Control ( IN-001005-01-05 ) or  
AntimiR ( IH-300580-0005 ) of hsa-miR-223 ( Thermo Scientific ), using Amaxa 
nucleofection . Protein were extracted 48 h post transfection as described in Western blot 
section. 
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3.12) Western Blot  
Pelleted cells were resuspended in lysis buffer ( Tris 20 mM pH 7.5, NaCl 150 mM, NaF 
1mM, Triton X-100 1%, Sodium-Orthovanadate 1 mM, PMSF 1mM, Sodium Butyrate 10mM) 
plus protease inhibitors for 20 mins on ice. After a centrifugation at 13000 rpm for 20 min, 
supernatants were boiled for 5 min in Laemmli sample buffer (Biorad, Hercules, CA, USA). 
Concentration of Protein was determined by Bradford (BioRad). 40 μg of protein was 
separated on 8% or 10% gel. After electrophoretic separation, proteins were electrotransferred 
on a Nitrocellulose membrane ( Perkin Elmer ). The membrane was then blocked for 1 h at 
room temperature with blocking agent 5% in TBS/Tween 0.05%, probed overnight with a 
primary antibodies against the proteins of interest, and finally revealed with a secondary 
antibodies HRP conjugated (Santa Cruz) and ECL Advance system (Cyanagen). The β actin 
or β tubulin were used as reference. 
 
3.13) miR-223 Promoter Construct  
The fragment containing the putative miR-223 promoter region was amplified by PCR from 
human genomic DNA using the primers :- 
Forward –5’CAAAGTCAACTACTTTCTTCTCCCTT 3’ 
Reverse  – 5’CCAGATGGAATTGGGCTTT 3’ 
The PCR products were separated by agarose gel electrophoresis, and DNA fragments were 
then isolated and and subcloned in topo TA-cloning vector (Invitrogen, Carlsbad, CA, USA). 
Minimal functional promoter were generated by cleaving with NdeI. The miR-223 promoter-
luciferase fusion plasmids were constructed by cleaving with NdeI and EcoRV and inserted 
into the NdeI and EcoRV sites upstream of the luciferase cDNA of pGL4-basic vector 
(Promega, Madison, WI, USA). 
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3.14) Mutagenesis 
Plasmid pGL4 containing miR-223 promoter fragment was used to generate mutant having 
the deletion of few base pair from the nested CSL/NFκB binding sites. The primers designed 
to introduce the site-directed mutation were : 
Forward -  5'-ccaggtttccctcaattattctaacctccttgacccac-3' 
Reverse  -  5'-gtgggtcaaggaggttagaataattgagggaaacctgg-3' 
The melting temperature (Tm) was calculated with the formula given by Stratagene 
(http://www.stratagene.com/manuals/200519.pdf). In brief, Two complimentary 
oligonucleotides containing the desired mutation flanked by unmodified nucleotide sequence 
were synthesized by PCR using 1µl of PfuUltra HF DNA polymerase. The extension reaction 
was initiated by pre-heating the reaction mixture to 95°C for 1 mins; 18 Cycles of 95°C for 50 
sec, 60°C for 50 sec, 68°C for 1 min followed by incubation at 68°C for 7 mins. 1 µl of Dpn I 
restriction enzyme was added and incubated at 37°C for 1 hours. 2 µl of Dpn I treated DNA 
was transferred to ultracompetant cells. Transformation was done with heat pulse for 30 sec at 
42°C. 0.5 ml of preheated NZY
+
 broth was added and incubated at 37°C for 1 hr. 
Transformant was plated and selected by Amphicillin. A total of 10 colonies were selected 
and their plasmids were isolated by mini-prep. The positive mutants were selected by 
respective restriction enzymatic digestion. The mutation was detected by sequencing.  
 
3.15) Cell cycle , Cell growth and Apoptosis Assay 
Cell Cycle analysis was done by using 7AAD (A9400) (Sigma Aldrich).. In Brief, the cells 
were washed with PBS and Fixation/Permeabilization solution (eBioscience, San Diego, CA, 
USA), was added. It was vortexed and stored at 4°C for 2 hours. Then washed 2 times with 
Permeabilization buffer (eBioscience, San Diego, CA, USA). After eliminating supernatant 
7AAD solution was added and incubated at Room Temperature for 30mins (or Overnight). To 
access cell growth, trypan blue was used to count the viable cell number. Apoptosis was 
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detected by using Annexin V Apoptosis Detection Kit (00-6990; eBioscience, San Diego, CA, 
USA).  
 
3.16) Cell sorting 
Thymocyte suspensions from wt and Notch3
IC
 tg mice were prepared and stained with anti-
CD4-FITC and anti-CD8-PE antibodies as described before. CD4
+
CD8
+
 DP subsets were then 
isolated (purity level 95%) with the FACSAria cell sorter (BD Biosciences). 
 
3.17) Chromatin Immunoprecipitation (ChIP) 
Protein complexes were cross-linked to DNA in living nuclei by adding formaldehyde 
(Sigma, Inc.) directly to fresh Jurkat cell lines to a final concentration of 1%. Crosslinking 
was allowed to proceed for 10 min at 37°C and was then stopped by the addition of glycine to 
a final concentration of 0.125 M. Cross-linked cells were washed twice with phosphate-
buffered saline and pelletted. Nuclei were extract with a buffer containing 10 mM Tris pH 8, 
0,25% Triton-X 100, 10 mM Na-EDTA, 0.5 mM Na-EGTA and protease inhibitors, pelleted 
by microcentrifugation and lysed by incubation in SDS lysis buffer (0.5% sodium dodecyl 
sulfate, 5 mM Na-EDTA, 50 mM Trischloride pH 8), containing protease inhibitors. The 
resulting chromatin solution was sonicated for 18 pulses of 15 s at 80% power to generate 
300–1000 bp DNA fragments. After microcentrifugation, the supernatant was diluted 1 5 with 
a dilution buffer (0.01% sodium dodecyl sulfate, 1% Triton X-100, 1 mM EDTA, 20 mM 
Tris-chloride pH 8, 150 mM NaCl, containing protease inhibitors), and aliquoted. After 
precleaning with Salmon Sperm DNA/Protein agarose (Upstate Biotechnology) 5 µg of anti-
RBPJκ or normal rabbit IgG, anti-p65 or normal mouse (Santa Cruz Biotechnology Inc.) were 
added to each aliquot of chromatin and incubated on a rotating platform for 12–16 h at 4°C. 
Antibody–protein–DNA complexes were isolated by immunoprecipitation with Salmon 
44 
 
Sperm DNA/Protein agarose (Upstate Biotechnology). Following extensive washing, bound 
DNA fragments were eluted and analyzed by subsequent PCR with the following primers:  
Forward  5’ GTGATTTGGAGTCCATGGGG 3’ 
Reverse  5’ ACCAACTCCCAGCTGACCTTC 3’ 
 
3.18) Transduction of cells with lentiviral vectors.  
 
The silencing of Notch3 in Human leukemia Molt3 cell lines was done with pLKO-puro-
IPTG-1xLacO lentivirus particles expressing shRNA for human Notch3 (TRCN0000020234, 
Sigma Aldrich). In brief, lentivirus particles was added to the Molt3 cell lines. The cells were 
centrifuged at 800 x g for 30 minutes at 32 °C. Each cell pellet was resuspended in 2 mL of 
media by gently pipetting the pellet up and down, and each resuspended pellet was transferred 
to its own well in a 6-well plate tissue culture plate. The negative selection of the transduction 
was done by puromycin. Cells were maintained in puromycin until the non-transduced 
negative control cells have died as determined by inspection or Trypan Blue staining. After 
the transduction, the transfectants were selected for 7 days with puromycin (2μg/ml) followed 
by the treatment with IPTG for induction of shRNA against Notch3. 
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4. Results 
4.1) Microarray profiling of Notch-regulated miRNAs in T-ALL 
Aimed to characterize miRNAs that are regulated by Notch signaling in T-ALL leukemia, we 
carried out miRNA expression profiling of freshly isolated double positive CD4
+
CD8
+
 (DP) 
thymocytes from 6-weeks-old wild type and N3
IC
 tg mouse T-ALL developing models [61]. 
As shown in Figure 10A, in all the mice analyzed, the thymocytes subset distribution is 
similar with respect to CD4 and/or CD8 expression. The overexpression of the N3
IC
 in the DP 
thymocytes from the transgenic mice was verified by the western blot when compared to wild 
type mice. The Notch1 expression was same in DP thymocytes from both N3
IC
 transgenic 
mice and wild type mice (Figure 10B). The overexpression of N3
IC
 protein in DP thymocytes 
from transgenic mice is correlated with the increased mRNA expression of known Notch 
target genes such as Hes1 and pTα when compared with the wt counterparts (Figure 10C). 
Total RNA was then isolated and the expression of genomic miRNAs was analyzed by qRT-
PCR using rodent TaqMan Low Density miRNA Arrays (TLDA). Data analyzed by 
RealTime StatMiner™ v3 software (Integromics™ SL, Spain) revealed a significant up-
regulation, of up to two folds, of 40 miRNAs and a considerable downregulation, of up of two 
fold, of 4 miRNAs (adjusted P value < 0.7) (Table 4). The unsupervised hierarchical 
clustering analysis shows that the strongest significantly up-regulated miRNAs, in N3
IC
 tg 
when compared with the wt DP thymocytes, were miR-337-5p, miR-31, miR-223 and miR-
146a and the more significative down-regulated were miR-150, miR-700, miR-126-3p and 
miR-378 (Figure 11). Subsequently, immature murine M31 T cells [191] were transiently 
transfected with the N3
IC
 or N1
IC
 plasmid (Figure 12A) to simulate the Notch pathway 
activation. As shown in figure 12B the forced expression of the activated Notch domains 
resulted in the increased expression of the Notch target genes Hes1 and c-Myc when 
compared with the control vector transfected cells. Total RNA from these samples were 
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isolated and analyzed for the expression of differentially regulated miRNAs by qRT-PCR 
using rodent TLDA. Amplification plots which did not amplify in all the samples, or/and had 
very high variation, or/and which expression was too low was excluded from the analysis by 
manual inspection. Relative miRNAs expression was normalized against the endogenous 
control U6 snRNA using the comparative ΔΔCT method and calculated by using SDS RQ 
manager ver. 1.2 software. As shown in Table 5, 92 miRNAs were upregulated and 60 
miRNAs were downregulated when compared between N3
IC
 vs pCDNA transfected M31 T 
cells as their expression levels varied up to two fold. The unsupervised hierarchical clustering 
analysis showed that, in N3
IC
 transfected M31 T cells when compared with the control vector 
transfected cells, the strongest up-regulated miRNAs were miR-223, miR-875 and miR-452 
and the more significative down-regulated miRNAs were miR-665, miR-let7-c-1 and miR-
694 (Figure 12C).  In order to evaluate the ability of Notch3 to regulate specific miRNAs, 
Notch3 expression was, also, ectopically silenced in either Molt3 and Jurkat human leukemia 
T cell lines, known to express Notch3, as shown Figure 13A and 14A. The strength of the 
silencing was valuated by the downregulation of Notch target genes expression (Figure 13B 
and 14B). The total RNA from the above samples was subjected to miRNA profiling by qRT-
PCR using human TLDA and then analyzed manually as previously described for the M31 T 
cells. The result revealed 236 miRNAs upregulated and 199 miRNAs downregulated in Molt3 
T cell lines (Table 6) and 34 miRNAs upregulated and 130 miRNAs downregulated in Jurkat 
T cell lines lines (Table 7), as their expression levels varied up to two fold. 
The subsequent unsupervised Hierarchical clustering of miRNAs differentially expressed 
between the Notch3 silenced cell lines versus the controls showed that the strongest up-
regulated miRNAs were miR-497*, miR-144 and miR-34c-5p in Molt3 and miR-137, miR-
628-5p, and miR-299-3p in Jurkat and the more significative down-regulated miRNAs were 
miR-892b, miR-1267 and miR-1276 in Molt3 (Figure 13C) and miR-1267, miR-198 and 
miR-127-3p in Jurkat cell lines (Figure 14C). Interestingly, according to Venn diagram 
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analysis, there are 11 miRNAs, which were commonly upregulated in N3
IC
 overexpressed 
models (Figure 15A). Moreover, the intersection of the miRNAs profile of Molt3 and Jurkat 
silenced for Notch3 revealed 95 miRNAs, which were commonly downregulated (Figure 
15B). Finally, as shown in Figure 15C and in Table 1, only 7 miRNAs were significantly 
modulated in response to either N3
IC
 overexpression or Notch3 silencing. The putative 
promoter analysis on these miRNAs showed only miR-223 and miR-139 to contain the 
RBPJκ/CSL binding site in both human and mouse, and miR-182 which is a member of 
cluster miR-183/93/182 contain CSL/RBPJκ binding site only in Mouse, thus showing non 
conservation of CSL/RBPJκ binding site, in the putative promoter of clustered miR-182 
(Table 3). The literature reviewed did not gave any much information regarding the oncogenic 
role miR-139-5p in T-ALL. Interesting it was previously shown that ectopic expression of 
miR-223 on hematopoietic lineage differentiation in vitro increased T-lymphoid lineage with 
little or no reduction in the B-lymphoid [192]. In another study cross-comparison of miRNAs 
expression profiles in human T-ALL identified miR-223 as one of the highest expressed 
miRNA in T-ALL. Moreover, the same authors indicated its oncogenic role in cancer 
promotion in a mouse model of T-ALL leukemia by regulating the expression of the E3 ligase 
FBW7 [188]. The above results showing miR-223 modulations by TLDA microfluid cards 
were reconfirmed through qRT-PCR by specific stem-loop primers for miR-223 (Figure 16) 
on all the above mentioned models. These evidences made us to focalize the study on the 
relation between Notch signaling and miR-223 regulation and its role in T-ALL context. 
 
4.2) miR-223 expression is regulated by Notch and NFKB signalling pathway. 
The locus of miR-223 maps on the X chromosome and is transcribed independently of any 
recognized genes [193] [194]. Independent studies were focalized on the regulation of miR-
223 revealing the transcriptional activation by CAAT enhancer-binding protein alpha 
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(C/EBP). Fazi and his colleagues proposed that C/EBP and the Nuclear Factor I-A (NFIA) 
regulate miR-223 expression competing for the same binding site 709 bp upstream of the pre-
miR-223 sequence [193].  Controversy, Fukao et al. demonstrated that the miR-223 
transcription is regulated by C/EBP and PU.1 located 3420 bp in front the pre-miR in a 
conserved promoter region upstream the transcription start site of the pri-miR [194]. A very 
recent study confirmed that the miR-223 expression is mostly regulated by the promoter 
region upstream the transcription start of the pri-miR suggesting that the previously described 
promoter region could represent a regulatory region [195]. Subsequently in-silico analysis, by 
Genomatix Maltinspector software, of the conserved human pri-miR-223 5’ proximal 
genomic region, confirmed the C/EBP and PU.1 consensus binding sites at 39bp and 51/ 63bp 
respectively, as previously demonstrated. Interesting, the analysis revealed a novel putative 
RBPJκ/CSL and NFκB-p65 overlapping evolutionary conserved binding sites between 280-
299 bp upstream the transcription start site of the pri-miR (Figure 17A). In order to 
investigate the role of the Notch signaling in the transcriptional regulation of the miR-223, we 
generated a luciferase reporter vector containing 690bp of the human pri-miR-223 5’ 
proximal genomic region (Figure 17B) or mutant construct which lack the consensus binding 
site for CSL/RBPJK nested with p65 (Figure 17C). The bonafide promoter region was 
confirmed by transfecting HEK293T cell lines with or without human-C/EBP-α expression 
vector (Figure 17D). As expected, the ectopic overexpression of Notch3 transcriptional 
complex or p65-NFκB resulted in an increased activity of the luciferase reporter, moreover 
co-expression of Notch3 transcriptional complex with p65-NFκB displayed a synergic effect 
on the promoter activation (Figure 17D) . Notably, the p65-induced promoter activity was 
dramatically decreased, when HEK-293T cells were transiently transfected with a deletion 
mutant reporter that lack the nested RBPJκ/CSL/NFκB consensus binding site (Mut miR-223 
promoter), but unexpectedly the same effect was not seen by Notch3 transcriptional complex,  
suggesting that this nested RBPJκ/CSL/NFκB consensus binding site is more important for 
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p65-NFκB mediated transcriptional regulation (Figure 17D). In order to understand the 
relationship between Notch and NFκB in the regulation of miR-223, we performed an in vivo, 
chromatin immunoprecipitation assay using sonicated chromatin from Jurkat Human 
Leukemia T cell lines. Chromatin extracts were administered to immunoprecipitation with 
both anti–RBPJκ/CSL or anti-p65-NFκB antibodies and subjected to PCR amplification with 
the use of specific primers that amplified the region containing the RBPJκ/CSL and NFκB 
binding region of the miR-223 promoter. As shown in Figure 18A, only anti-p65 antibody 
recovered a 300-bp fragment of the proximal promoter containing the previously described 
binding site, while no signal was detected in PCR of RBPJκ/CSL immunoprecipitated DNA 
fragment suggesting that p65 play a direct role in transcriptional regulation of miR-223, in 
contrast to Notch transcriptional complex which  could either regulate miR-223 through other 
mechanism independently of this RBPJκ/CSL and NFκB binding region or could play an 
indirect role in the transcriptional regulation of miRNA-223 likely through the activation of 
NFκB signaling which for its part is able to do this directly by binding to the promoter. In 
order to deepen our understanding on the direct role of p65 in transcriptional regulation of 
miR-223, we tried to use phosphorylation-defective IkBα S32A/S36A (IKBα PD) that is 
known to sequester NFκB in cytoplasm [196]. As shown in (Figure18B) co-transfecting p65 
with IKBα PD  completely abrogated miR-223 promoter activation. Moreover, the NFκB 
pharmacological inhibition using BAY11-7082 or activation using 12-O-tetradecanoyl 
phorbol-13-acetate (TPA) resulted respectively in the inhibition or in the activation of the 
endogenous miR-223 expression in Jurkat cells lines (Figure 18C).  
Our previous works demonstrated the ability of Notch3 to trigger the canonical p65-NFκB 
pathway [189] [197], confirming, on one hand, that NFκB signaling plays a key role in miR-
223 transcriptional regulation in T-ALL leukemia other than C/EBP and PU.1 known 
regulatory pathways in acute myeloid leukemia (AML) and, on the other hand, in this 
regulatory mechanism Notch signaling plays an important role indirectly by activating the 
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NFκB signaling. In detail, these results demonstrate that the transcriptional regulation of miR-
223 is mainly linked to the activity of NFκB that directly activates the promoter. Therefore, in 
contexts in which the activity of NFκB is closely dependent on the Notch pathway activation, 
as demostrated in several human cell lines and murine models of T-ALL leukemia where 
NFκB, it was identified as one of the major mediators of Notch-induced tumorigenesis [198], 
[199] [61] [189], Notch could have a key role in the miR-223 gene expression. 
 
4.3) miR-223 plays a role in regulating cell growth of T-ALL. 
In the last years, emerging evidence suggested miR-223 as novel oncogene by directly 
targeting the onco-suppressor FBXW7/hCdc4 (FBXW7) in different tumor contexts such as 
human gastric cancer [200], in oesophageal squamous cell carcinoma [201] in primary mouse 
embryo fibroblasts [202]. Moreover, loss of functional mutations in Fbxw7 were linked with 
many human diseases and tumors including T-ALL [203] [204].  Interestingly, the enforced 
over-expression of the mimic-miR-223 in Jurkat T cell resulted in remarkable decrease of the 
FBXW7 protein expression and conversely, the inhibition of the miR-223 by antago-miR-223 
increased the FBXW7 expression (Figure 19A).  
Notably, several studies have revealed multiple targets of the FBXW7 ubiquitin ligase activity 
[205] [206] [207] [208] [202] which are known plays pivotal roles in many key cellular 
processes including cell proliferation, differentiation and apoptosis, and were founded often 
deregulate in a wide range of human cancers [209]. Consistently, the FBXW7 modulation in 
miR-223-induced Jurkat T cells caused the substantial regulation of all the previously 
mentioned FBXW-7 target proteins. As shown in Figure 19A, Jurkat T cells transfected with 
the mimic-miR-223 resulted in the increased protein levels of the Notch1 intracellular domain 
(N1
IC
), c-Myc and Cyclin E while the inhibition of the miR by transfecting antago-miR-223 
caused the opposite effects. Aditionally, the cell number was increased in Jurkat T cells 
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transfected with the mimic-miR-223 when compared to it relative control, thus showing 
increased cell growth (Figure 19B). While the reverse effect was seen with antagomiR as the 
cell growth decreased (Figure 19C). Moreover, cell cycle analysis by flow cytometry showed 
decreased number of cells accumulated in G0/G1 phase (from 51% to 43%) and increased in 
S phase (from 27% to 37%) comparing transfected cells with mimic-miR-223 to the controls 
cells (Figure 19D) without affecting the apoptosis rate (Figure 19E). Overall, these results 
demonstrated that mir-223 inhibiting the tumor suppressor FBWXW-7 expression stimulates 
Jurkat T cell proliferation, revealing for the first time its oncogenic role in T-cell Leukemia. 
 
4.4) miR-223 confers resistance to ᵞ-secretase inhibition in  T-ALL cell lines. 
In quest to see the effect of inhibition of Notch signalling on miR-223 expression, we utilise 
γ-Secretase inhibitor IX (DAPT), a chemical compound, which is known as strong inhibitors 
of the Notch signalling, unexpectedly we saw an increase in endogenous expression of miR-
223 in both Jurkat and Molt3 cell lines (Figure 20A & 20B). Consistently a recent publication 
also revelled increase in miR-223 expression when the T-ALL cell lines where treated with 
Compound E (another γ-Secretase inhibitor) [210]. This result was completely opposite to 
what we observed when we specifically inhibited Notch3 using specific siRNA. The solution 
of this dilemma was unveiled by the subsequently comparison of the Notch1 activated form 
and the phosphorylated p65-NFkB protein expression between Jurkat and Molt3 T cells 
DAPT-treated versus the control cells. As shown in Figure 20C, although DAPT inhibited 
Notch signalling by blocking the Notch S3 cleavage, simultaneously, it induced the activation 
of the NFkB canonical signaling.  
Furthermore, analysis of miR-223 expression showed a reduced transcription of this miR in 
stable cell line of Jurkat in which the NFκB signaling was inhibited by the silencing of IKKγ 
(Jurkat IKKγ-/-) when compared with wt counterpart Jurkat T cell lines (Figure 21A). The 
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inhibition of NFkB signalling was confirmed by the decreased phosphorylation of p65-NFkB 
and by the increased accumulation of IKBα in the total extracts from the Jurkat IKKγ-/- when 
compared with the Jurkat wt. (Figure 21A). Cell count of viable cell using trypan blue 
staining showed decreased cell number in Jurkat IKKᵞ-/- (Figure 21B), which had a low 
expression of miR-223 when compared to Jurkat wt, thus indicating that miR-223 could play 
a role cell growth and proliferation. To access the role of miR223 in rendering sensitivity to 
GSI resistant cell, we treated Jurkat wild type and Jurkat IKKγ-/- cell lines with DMSO and 
GSI-IX (DAPT), and accessed their growth rate every 2 days until day 14. As shown in 
Figure 21C, Jurkat wild type cell lines treated with DAPT or DMSO, both continued to grow 
normally. Instead Jurkat IKKγ-/- cell line showed decreased growth rate when they were 
treated with DAPT in comparison to its counterpart DMSO treated (Figure 21D).  
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                                                                                  A 
                                 
                             B                                                                                          C  
Figure 10 : N3
IC
 and its target gene expression in DP Thymocytes from N3
IC
 transgenic Mice : 
A) CD4
+ 
and/or CD8
+
 subset distribution of thymocytes derived from N3
IC 
Transgenic and Wild Type 
(wt) mice. B) Western blot analysis of whole-cell extracts from the sorted DP thymocytes form 
Transgenic and wild type mice, probed with Notch3 & Notch1 antibodies. The α-Tubulin expression 
was used as loading control. C) Relative  mRNA expression of  Notch3 downstream target genes as 
analyzed by RT-PCR. Data are represented as mean ± s.d. from triplicate tests. *P<0.05; **P<0.01. 
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Figure 11 : Heat map shows distinct miRNAs expression profiles in N3
IC
 Trasngenic  mice 
relative to wild-type (WT) counterpart : Each column represents one of three RNA samples and 
each row represents one miRNA gene. Relatedness in miRNA expression across samples is shown by 
a hierarchical tree on the Y axis through standard linkage. Expression levels are depicted according to 
the color scale at the bottom with increased expression ranging from green to red. 
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Figure 12 : Differential miRNAs expression profiling of M31 T Cell lines overexpressed with 
N3
IC
 , N1
IC
 or empty vector : A) Western blot against N3
IC
 or N1
IC
 confirmed transfection and 
overexpression of N3
IC
 or N1
IC
 protein. B) RT-PCR shows increased mRNA expression of Notch 
target gene in N3
IC
 or N1
IC
 transfected M31 Cell lines compared to M31 transfected with only empty 
vector. C) Heat map shows genomic miRNAs expression profiles of M31 transfected with N3
IC
 or 
N1
IC
 relative to pcDNA empty vector. Each column represents one RNA samples and each row 
represents one miRNA gene. Relatedness in miRNA expression across samples is shown by a 
hierarchical tree on the Y axis through standard linkage. Expression levels are depicted according to 
the color scale at the bottom with increased expression ranging from green to red. 
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Figure 13 : Silencing of N3
IC
 in Molt3 showed distinct set of miRNAs which were modulated: A) 
Western blot against N3
IC
 showing efficiency of Notch3 silencing by lentivirus. The silencing was 
induced by treatment with IPTG. N1
IC
 protein expression level showed no modulation . B) RT-PCR 
shows down modulation of  Notch target gene in N3
IC
 silenced Molt3 IPTG treated cell lines 
compared to untreated counterpart. C) Heat map shows differential regulated miRNAs expression 
profiles of Molt3 IPTG treated and untreated samples. Each column represents one RNA samples and 
each row represents one miRNA gene. Relatedness in miRNA expression across samples is shown by 
a hierarchical tree on the Y axis through standard linkage. Expression levels are depicted according to 
the colour scale at the bottom with increased expression ranging from green to red. 
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Figure 14 : Silencing of Notch3 in Jurkat shows significant effect on differential expression of 
miRNAs: Western blot against N3
IC
 and N1
IC
 showing efficiency of Notch3 transient silencing by 
siRNA without affecting the N1
IC
 protein expression level. B) RT-PCR shows down modulation of  
Notch target gene in N3
IC
 silenced Jurkat to Control counterpart. C) Heat map shows genomic 
miRNAs expression profiles of Notch3 silenced Jurkat relative to control sample . Each column 
represents one RNA samples and each row represents one miRNA gene. Relatedness in miRNA 
expression across samples is shown by a hierarchical tree on the Y axis through standard linkage. 
Expression levels are depicted according to the colour scale at the bottom with increased expression 
ranging from green to red. 
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Figure 15 : Notch3 affects expression of specific miRNAs in both Human and Mouse T Cell 
Leukemia Models. (a) The Venn diagram shows the number of the significantly up-regulated 
miRNAs caused by Notch3 overexpression. The intersection gives a view of miRNAs that are induced 
in response to Notch3. (b)The Venn diagram shows the number of significantly down-regulated 
miRNAs resulted from Notch3 interference. The intersection gives a view of miRNAs that are 
decreased in response to Notch3 silencing. (c) The Venn diagram shows the number of significantly 
modulated miRNAs in response to either Notch3 overexpression and its silencing. The intersection 
gives a direct view of the miRNA that are positively regulated by N3 signaling.  
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Table 2 : Relative expression level of  7 miRNAs positively regulated by Notch3 Signalling 
miRNA Tg Mice N3 M31 N3IC Jurkat siN3 Molt3 siN3 
miR-223 10,5385 16634,7850 0,5113 0,2642 
miR-182 3,2713 2,1239 0,5008 0,5346 
let-7d 2,4870 2,0882 0,5222 0,2639 
miR-425 4,0177 2,0806 0,5044 0,5394 
miR-25 3,3795 2,0681 0,5074 0,5433 
miR-139-5p 8,1822 2,0525 0,5150 0,5431 
miR-103 2,5001 2,1346 0,5077 0,2752 
 
 
Table 3 : Chromosomal location of 7 regulated miRNAs and CSL/RBPJK binding site in their 
putative promoter region 
    
CSL/RBPJκ 
miRNA Chrom Loc Hum Chrom Loc Mouse Host gene name Human  Mouse  
miR-223 chrX: 65238712-65238821 chrX: 96242817-96242926 AL034397.1 yes yes 
miR-182 chr7: 129410223-129410332 [-] chr6: 30165918-30165992 [-] - no yes 
let-7d chr9: 96941116-96941202 [+] chr13: 48536012-48536114 [-] RP11-2B6.1 no no 
miR-425 chr3: 49057581-49057667 [-] chr9: 108568777-108568861 [+] DALRD3 - - 
miR-25 chr7: 99691183-99691266 [-] chr5: 138165321-138165404 [-] MCM7 no no 
miR-139-5p chr11: 72326107-72326174 [-] chr7: 101475376-101475443 [+] PDE2A yes yes 
miR-103 - - PANK2 no no 
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              Thymocytes                        M31cell line                           Molt3                                     Jurkat 
 
Figure 16 : miR-223 expression is dependent on Notch3 signaling in both human and mouse 
models of leukemia. The level of miR-223 was compared by quantitative RT-PCR in: (A) DP 
Thymocytes from tgN3
IC 
mice versus wt mice, (B) M31 T cell lines N3
IC 
transfected versus control 
vector transfected, (C) Molt3 and (D) Jurkat T cell lines Notch silenced respectively versus the control 
cells. Data are represented as mean ± s.d. from triplicate tests. *P<0.05; **P<0.01. 
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Graphic  representation of the miR-223 promoter gene location 
TSS miR-223pre-Mir-223pri-Mir-223
RBPJk/CBF1 NFkB-p65
Human                       CCCTCAATTATTCTGGGAAAACC
Rhesus   (100%)       CCCTCAATTATTCTGGGAAAACC
Lemur    (90%)          CCCTCAGTTACTCTGGGAAAACC
Mouse   (78%)          CCCTCAATTGCTCTAGGGAAACT
Rat          (74%)          CCCTCAGTTGCTCTAGGGAAACT
Dolphin  (78%)         CCTTCAGTAAATCTGGGGAAACC
-280bp-299bp
A
B
D
C
 
Figure 17 : Regulation of human miR-223 by Notch3 and NFκB (p65)  
A)Graphical representation of human miR-223 promoter region. Conserved regions are shown as 
green peak as retrieved from USCS genome browser. RBPJκ and NFκB binding site in conserved 
region are shown in Blue and Pink and their intersection shows nested region. B) Schematic 
representation of the miR-223 promoter reporter constructs. The putative consensus site for C/EBPα 
from -39bp to -48bp and the nested binding site RPBJκ/NFkB from -280bp to -299bp from the start of 
transcription, fixed as +1bp, are indicated by boxes (wt miR-223 promoter).C)  The dotted line refers 
to the internal deletion generated inside the RPBJκ /NFkB from -280bp to -286bp of the mutated Δ 
miR-223 promoter. D) Luciferase assay performed on HEK 293T cells after the co-transfection with a 
luciferase reporter construct containing the wt or mutated hsa-miR-223 promoter and  C/EBPα, N3IC, 
or NFkB-p65 vectors. (C/EBPα is used as Positive control). The results showed in the figure are 
expressed as the means average deviations of three separate experiments and bars indicate s.d. 
*P<0.05; **P<0.01, ***P<0.001. 
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Figure 18 : NFκB (p65) directly regulate human miR-223 expression : A) Jurkat T cells were 
processed for chromatin preparation and then subjected to immunoprecipitation with antibodies 
against either NFkB-p65 , RBPJκ or IgG as control . The immunoprecipitates were analyzed by PCR 
with human miR-223 promoter-specific primers. The upper panels show the relative quantification as 
determined by optical densitometry (OD). Schematic representation of miR-223 promoter regions 
assessed by chromatin immunoprecipitation is indicated in the lower panel. B) Luciferase assay 
performed on HEK 293T cells after the co-transfection with a luciferase reporter construct containing 
the wt miR-223 promoter, NFkB-p65 and IKBα PD alone or in combination. C) The expression levels 
of endogenous miR-223 in Jurkat T cells treated with either TPA, BA-Y11-7082 or with the vehicle 
alone were examined by quantitative real-time RT-PCR as detailed in the Material and Methods. All 
the results showed in the figures are expressed as the means average deviations of three separate 
experiments and bars indicate s.d. *P<0.05; **P<0.01, ***P<0.001. 
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Figure 19 : miR-223 affects cell cycle by repressing FBXW7   
A)Expression level of FBXW7 and its downstream target proteins such as Notch1
 
, c-Myc,  and 
CyclinE as analysed by western blot against anti-Notch1, anti-c-Myc, and anti-CyclinE, in Jurkat 
transient transfected with either miR-223 Mimic or Antago-miR and relative controls.  B)Increased 
cell growth of Jurkat transfected with Mimic of miR-223 compared to jurkat transfected with Control, 
as shown by the cell count using trypan blue staining .C) Decreased cell growth of Jurkat transfected 
with antago-miR of miR-223 compared to Jurkat transfected with Control, as shown by the cell count 
using trypan blue staining. D & E) Jurkat cells transiently transfected with mimic of miR-223 or 
control subjected to fluorescence-activated cell sorting (FACS) analysis for cell cycle or Annexin 
assay for Appoptosis. 
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Figure 20 : GSI treatment induce miR-223 expression through NFκB pathway: A) & B) Relative 
expression of endogenous miR-223 in GSI IX or DMSO treated Jurkat and Molt3 T-ALL cell lines. C) 
Whole cell extract from DMSO and GSI IX treated Jurkat cells were subjected to western blot against 
antibody for Val-Notch1 and Phospho-p65. β-actin is used as loading control. 
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Figure 21 : Stable Deletion of NFκB regulator IKKᵞ in Jurkat showed decreased miR-223 
expression and cell-growth: A) Upper panel : RT-PCR shows decreased expression of endogenous 
miR-223 in Jurkat IKKᵞ-/-   compared to Jurkat wild type (wt). Down panel : Western blot analysis of 
whole-cell extracts from Jurkat wt and Jurkat IKKγ-/- T cells probed with pospho-NFkB p65, IKKγ and 
IkBα antibodies. The α-actin expression was used as loading control. B) The graph shows decrease in 
cell growth of Jurkat IKKᵞ-/- compared to Jurkat wt until 14 days of culture as analysed by the cell 
count using trypan blue staining. C) Treatment with DMSO or GSI-IX (DAPT) in Jurkat wild type cell 
lines and its effect on cell growth as analysed by cell count until 14 days. D)  Treatment with DMSO 
or GSI-IX (DAPT) in Jurkat IKKᵞ-/- cell lines and its effect on cell growth as analysed by cell count 
until 14 days. 
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Table 4 : Differential regulated miRNAs in N3
IC
 Transgenic Mice relative to its wild type 
counterpart. 
Up-Regulated miRNAs 
 
Down-Regulated miRNAs 
miRNA  Detector code RQ (>2fold) P value 
 
miRNA  Detector code RQ  P value 
miR-337-5p 4395645 17,2411 1,5E-03 
 
miR-150 4373127 0,5366 6,31E-02 
miR-31 4373331 12,7473 5,1E-04 
 
miR-700 4381057 0,5917 5,16E-02 
miR-223 4395406 10,5385 2,0E-03 
 
miR-126-3p 4395339 0,7590 2,41E-01 
miR-146a 4373132 9,2801 1,0E-03 
 
miR-378 4395354 0,8920 6,81E-01 
miR-139-5p 4395400 8,1822 1,1E-03 
     miR-455* 4378098 7,8619 2,1E-02 
     miR-467b* 4381092 6,0277 3,7E-03 
     miR-501-3p 4381069 5,9578 4,2E-02 
     miR-29c 4395171 5,8174 3,4E-03 
     miR-342-3p 4395371 5,5059 1,9E-03 
     miR-361 4373035 5,1301 3,8E-03 
     miR-194 4373106 5,0249 1,1E-03 
     miR-590-5p 4395176 4,6243 8,9E-03 
     miR-21 4373090 4,4293 3,8E-02 
     miR-762 4395565 4,4134 4,7E-03 
     miR-200c 4395411 4,2655 3,8E-03 
     miR-425 4380926 4,0177 9,8E-03 
     miR-28 4373067 3,9939 6,6E-03 
     miR-138 4395395 3,4855 2,4E-03 
     miR-25 4373071 3,3795 4,7E-03 
     miR-182 4395729 3,2713 1,8E-02 
     miR-467c 4395647 3,2052 1,0E-02 
     miR-449a 4373207 3,0697 2,9E-02 
     miR-20b 4373263 2,8252 9,3E-03 
     miR-328 4373049 2,6988 1,2E-02 
     miR-92a 4373013 2,6931 5,3E-03 
     miR-181c 4373115 2,6809 2,0E-02 
     miR-98 4373009 2,6504 3,3E-02 
     miR-467b 4381084 2,6111 1,1E-02 
     miR-195 4373105 2,5059 1,2E-02 
     miR-103 4373158 2,5001 3,7E-02 
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let-7d 4395394 2,4870 9,6E-03 
     miR-135a* 4395343 2,4549 7,6E-03 
     miR-17 4395419 2,4072 2,0E-02 
     miR-106a 4395589 2,3132 2,0E-02 
     miR-132 4373143 2,3082 4,6E-02 
     let-7f 4373164 2,1927 4,3E-02 
     miR-687 4386750 2,1460 1,0E-02 
     miR-760 4395439 2,0921 1,6E-02 
     let-7g 4395393 2,0827 4,0E-02 
      
 
 
Table 5 : Differential regulated miRNAs in M31 Cell lines transiently transfected with N3
IC
  
relative to M31 transfected with empty vector pcDNA. 
Up-Regulated miRNAs 
 
Down-Regulated miRNAs 
miRNA Detector Code RQ (>2fold) Log 10 (RQ) 
 
miRNA Detector Code RQ (< 2fold) Log 10 (RQ) 
miR-223 4395406 16634,7850 4,2210 
 
miR-679 4381077 1,487E-05 -4,8277 
miR-546 4381044 1332,2702 3,1246 
 
miR-675-3p 4386762 1,601E-05 -4,7957 
miR-875-3p 4395677 691,1303 2,8396 
 
miR-363 4378090 1,821E-03 -2,7396 
let-7g* 4395622 650,5439 2,8133 
 
miR-665 4395737 4,566E-03 -2,3405 
miR-742 4395573 641,8850 2,8075 
 
miR-743a 4395599 4,995E-03 -2,3014 
miR-99a 4373008 346,1544 2,5393 
 
miR-9 4373285 1,122E-02 -1,9500 
miR-452 4373281 133,5740 2,1257 
 
let-7c-1* 4395609 1,373E-02 -1,8625 
miR-497 4381046 128,3268 2,1083 
 
miR-411 4381013 1,869E-02 -1,7284 
miR-451 4373360 89,6460 1,9525 
 
miR-101a* 4395637 2,067E-02 -1,6846 
miR-15a 4373123 28,4902 1,4547 
 
miR-694 4381090 2,924E-02 -1,5340 
miR-701 4381058 15,9166 1,2019 
 
miR-127 4373147 3,021E-02 -1,5199 
miR-681 4381080 14,7949 1,1701 
 
miR-196a* 4395607 4,981E-02 -1,3027 
miR-674* 4386773 14,5647 1,1633 
 
miR-106b* 4395491 1,240E-01 -0,9066 
miR-698 4381055 12,3537 1,0918 
 
miR-702 4381059 1,395E-01 -0,8553 
miR-672 4395438 12,3158 1,0905 
 
miR-875-5p 4395314 1,411E-01 -0,8506 
miR-92a* 4395626 9,4531 0,9756 
 
miR-708* 4395453 1,956E-01 -0,7087 
miR-151-3p 4373304 8,6860 0,9388 
 
miR-878-3p 4395671 2,123E-01 -0,6730 
miR-582-3p 4395697 8,4844 0,9286 
 
miR-186* 4395704 2,148E-01 -0,6679 
miR-409-3p 4395443 7,7586 0,8898 
 
miR-721 4381073 2,228E-01 -0,6521 
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miR-297c 4395610 5,8229 0,7651 
 
miR-467e 4395698 2,421E-01 -0,6161 
miR-206 4373092 5,7802 0,7619 
 
miR-501-3p 4381069 2,513E-01 -0,5998 
miR-335-3p 4395296 4,9526 0,6948 
 
miR-197 4373102 2,522E-01 -0,5983 
miR-450b-5p 4386779 4,6840 0,6706 
 
miR-671-3p 4395433 2,552E-01 -0,5932 
miR-539 4378103 4,6084 0,6636 
 
miR-509-3p 4395651 2,584E-01 -0,5877 
miR-380-5p 4395731 4,5820 0,6611 
 
miR-138 4395395 2,588E-01 -0,5871 
miR-125a-5p 4395309 4,3750 0,6410 
 
miR-34b-3p 4395748 2,602E-01 -0,5846 
miR-322* 4395636 4,1529 0,6183 
 
miR-193b 4395597 2,645E-01 -0,5776 
miR-99b* 4395307 3,9656 0,5983 
 
miR-697 4381054 2,690E-01 -0,5703 
miR-676 4386776 3,8213 0,5822 
 
miR-294* 4395725 3,059E-01 -0,5144 
miR-218 4373081 3,7559 0,5747 
 
miR-208 4373091 3,121E-01 -0,5057 
miR-31 4373331 3,7463 0,5736 
 
miR-801 4395562 3,360E-01 -0,4736 
miR-191* 4395706 3,1237 0,4947 
 
miR-449c 4386747 3,565E-01 -0,4480 
miR-330* 4373337 2,8549 0,4556 
 
miR-17* 4395673 3,667E-01 -0,4357 
miR-449b 4395669 2,6087 0,4164 
 
miR-27b* 4395285 3,855E-01 -0,4140 
miR-673-5p 4386772 2,5662 0,4093 
 
miR-141 4373137 3,860E-01 -0,4134 
miR-200a 4378069 2,3016 0,3620 
 
miR-190b 4395374 4,496E-01 -0,3472 
miR-491 4381053 2,2319 0,3487 
 
miR-383 4381093 4,841E-01 -0,3151 
miR-331-5p 4395344 2,2096 0,3443 
 
miR-361 4373035 5,028E-01 -0,2986 
miR-375 4373027 2,1795 0,3384 
 
miR-501-5p 4381048 5,034E-01 -0,2981 
miR-181a 4373117 2,1741 0,3373 
 
miR-7a* 4381118 5,085E-01 -0,2937 
miR-297a* 4395584 2,1503 0,3325 
 
miR-7a 4378130 5,089E-01 -0,2933 
miR-181a-1* 4373086 2,1404 0,3305 
 
miR-23b 4373073 5,110E-01 -0,2916 
miR-103 4373158 2,1346 0,3293 
 
miR-466c-5p 4395631 5,120E-01 -0,2907 
miR-365 4373194 2,1269 0,3277 
 
miR-503 4395586 5,139E-01 -0,2891 
miR-182 4395729 2,1239 0,3271 
 
let-7d* 4378108 5,165E-01 -0,2869 
miR-450a-5p 4395414 2,1068 0,3236 
 
miR-547 4395694 5,167E-01 -0,2867 
miR-467b* 4381092 2,1031 0,3229 
 
miR-33* 4395247 5,176E-01 -0,2860 
miR-106b 4373155 2,1021 0,3227 
 
miR-26b* 4395555 5,210E-01 -0,2831 
miR-185 4395382 2,0976 0,3217 
 
miR-590-5p 4395176 5,238E-01 -0,2808 
miR-19a 4373099 2,0882 0,3198 
 
miR-696 4381051 5,244E-01 -0,2803 
let-7d 4395394 2,0882 0,3198 
 
miR-22* 4395412 5,271E-01 -0,2781 
miR-532-3p 4395466 2,0867 0,3195 
 
let-7f* 4395528 5,316E-01 -0,2744 
miR-324-5p 4373052 2,0863 0,3194 
 
miR-34c* 4395714 5,358E-01 -0,2710 
miR-183 4395380 2,0807 0,3182 
 
miR-20a* 4395621 5,364E-01 -0,2705 
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miR-425 4380926 2,0806 0,3182 
 
miR-467e* 4395699 5,453E-01 -0,2634 
miR-339-5p 4395368 2,0786 0,3178 
 
miR-741 4395587 5,531E-01 -0,2572 
miR-328 4373049 2,0765 0,3173 
 
miR-805 4395577 5,584E-01 -0,2530 
miR-21* 4395623 2,0742 0,3169 
 
miR-666-5p 4386770 5,682E-01 -0,2455 
miR-574-3p 4395460 2,0735 0,3167 
 
ath-miR159a 4373390 5,741E-01 -0,2410 
miR-676* 4386775 2,0715 0,3163 
 
miR-699 4381056 5,895E-01 -0,2295 
miR-29a 4395223 2,0710 0,3162 
     miR-652 4395463 2,0701 0,3160 
     miR-25 4373071 2,0681 0,3156 
     miR-140 4373374 2,0647 0,3149 
     miR-27b 4373068 2,0624 0,3144 
     let-7b 4373168 2,0619 0,3143 
     miR-322 4378107 2,0618 0,3142 
     miR-26a 4395166 2,0612 0,3141 
     miR-467a 4395717 2,0612 0,3141 
     miR-142-5p 4395359 2,0563 0,3131 
     miR-24 4373072 2,0558 0,3130 
     let-7i 4395332 2,0548 0,3128 
     miR-708 4395452 2,0547 0,3127 
     miR-872* 4395672 2,0529 0,3124 
     miR-139-5p 4395400 2,0525 0,3123 
     miR-30c 4373060 2,0520 0,3122 
     let-7a 4373169 2,0516 0,3121 
     miR-872 4395375 2,0515 0,3121 
     miR-532-5p 4380928 2,0498 0,3117 
     miR-362-3p 4395746 2,0489 0,3115 
     miR-301a 4373064 2,0484 0,3114 
     miR-500 4395736 2,0482 0,3114 
     miR-188-5p 4395431 2,0481 0,3113 
     miR-32 4395220 2,0472 0,3112 
     miR-582-5p 4395696 2,0451 0,3107 
     let-7e 4395517 2,0426 0,3102 
     miR-30e* 4373057 2,0381 0,3092 
     miR-378 4395354 2,0295 0,3074 
     miR-27a 4373287 2,0293 0,3074 
     
70 
 
miR-467d 4395648 2,0271 0,3069 
     miR-467c 4395647 2,0061 0,3023 
     miR-881 4395739 2,0041 0,3019 
      
 
 
Table 6: Differential regulated miRNAs in Molt3 T-ALL cell lines stably transduced with 
shRNA for Notch3 relative to its control counterpart. 
Down-Regulated miRNAs 
 
Up-Regulated miRNAs 
miRNA Detector Code RQ (< 2fold) Log10 (RQ) 
 
miRNA Detector Code RQ (>2fold) Log10 (RQ) 
miR-892b 2214 7,260E-06 -5,1391 
 
miR-497# 2368 3897,4857 3,5908 
miR-1267 2885 1,416E-05 -4,8490 
 
miR-144 2676 1868,1169 3,2714 
miR-1276 2843 3,090E-05 -4,5100 
 
miR-34c-5p 4373036 633,2197 2,8016 
miR-1247 2893 8,262E-04 -3,0829 
 
ath-miR159a 4373390 336,0763 2,5264 
miR-520D-3P 2743 1,920E-03 -2,7168 
 
miR-1282 2803 112,9981 2,0531 
miR-525-5p 4378088 3,330E-03 -2,4776 
 
miR-665 2681 49,8670 1,6978 
miR-644 1596 7,042E-03 -2,1523 
 
miR-559 1527 32,0573 1,5059 
miR-1249 2868 1,355E-02 -1,8680 
 
miR-765 2643 30,3561 1,4822 
miR-522 4395524 2,942E-02 -1,5314 
 
let-7a# 2307 17,6805 1,2475 
miR-567 1534 2,967E-02 -1,5276 
 
miR-127-5p 4395340 13,7401 1,1380 
miR-496 4386771 3,210E-02 -1,4936 
 
miR-1301 2827 12,6245 1,1012 
miR-551b 4380945 5,282E-02 -1,2772 
 
miR-521 4373259 8,9110 0,9499 
miR-215 4373084 5,593E-02 -1,2523 
 
miR-219-1-3p 4395206 8,5010 0,9295 
miR-1292 2824 6,172E-02 -1,2096 
 
miR-151-3p 2254 7,7339 0,8884 
miR-18b 4395328 7,333E-02 -1,1347 
 
miR-520f 4373256 4,4012 0,6436 
miR-33a 2135 1,000E-01 -0,9998 
 
miR-519d 4395514 4,2449 0,6279 
miR-519e 4395481 1,106E-01 -0,9564 
 
miR-29b-2# 2166 4,1180 0,6147 
miR-539 4378103 1,127E-01 -0,9482 
 
miR-424# 2309 4,0478 0,6072 
let-7f-2# 2418 1,180E-01 -0,9280 
 
miR-1227 2769 3,9661 0,5984 
miR-520g 4373257 1,201E-01 -0,9206 
 
miR-589 1543 3,9111 0,5923 
miR-96 4373372 1,368E-01 -0,8638 
 
miR-1255B 2801 3,8809 0,5889 
miR-299-3p 4373189 1,665E-01 -0,7785 
 
miR-15a# 2419 3,8486 0,5853 
miR-1303 2792 2,334E-01 -0,6319 
 
miR-17# 2421 3,8481 0,5852 
miR-935 2178 2,343E-01 -0,6302 
 
miR-151-5P 2642 3,8442 0,5848 
miR-34a# 2316 2,346E-01 -0,6297 
 
miR-590-3P 2677 3,8373 0,5840 
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miR-204 4373094 2,374E-01 -0,6245 
 
miR-27a# 2445 3,8080 0,5807 
miR-523 4395497 2,411E-01 -0,6178 
 
miR-363# 1283 3,8035 0,5802 
miR-148b# 2160 2,424E-01 -0,6155 
 
miR-148a# 2134 3,7209 0,5706 
miR-190 4373110 2,428E-01 -0,6147 
 
miR-639 1583 3,7191 0,5704 
miR-181a 4373117 2,502E-01 -0,6017 
 
miR-662 1607 2,5298 0,4031 
miR-202 4395474 2,633E-01 -0,5795 
 
miR-1183 2841 2,4364 0,3868 
miR-374a 4373028 2,636E-01 -0,5791 
 
miR-1825 2907 2,3719 0,3751 
miR-19a 4373099 2,638E-01 -0,5787 
 
miR-628-5p 4395544 2,2537 0,3529 
let-7d 4395394 2,639E-01 -0,5786 
 
miR-487a 4378097 2,1139 0,3251 
miR-223 4395406 2,642E-01 -0,5781 
 
miR-99b 4373007 2,1088 0,3240 
miR-30c 4373060 2,652E-01 -0,5765 
 
miR-505 4395200 2,0022 0,3015 
miR-374b 4381045 2,658E-01 -0,5755 
 
miR-1253 2894 2,0015 0,3013 
miR-574-3p 4395460 2,659E-01 -0,5752 
     miR-501-5p 4373226 2,667E-01 -0,5740 
     miR-31 4395390 2,673E-01 -0,5730 
     miR-95 4373011 2,676E-01 -0,5726 
     miR-744 4395435 2,681E-01 -0,5718 
     miR-346 4373038 2,681E-01 -0,5717 
     miR-106b 4373155 2,682E-01 -0,5716 
     miR-579 4395509 2,688E-01 -0,5705 
     miR-27a 4373287 2,689E-01 -0,5704 
     miR-660 4380925 2,695E-01 -0,5694 
     miR-340 4395369 2,696E-01 -0,5693 
     miR-185 4395382 2,697E-01 -0,5691 
     miR-342-5p 4395258 2,702E-01 -0,5684 
     miR-494 4395476 2,712E-01 -0,5667 
     miR-107 4373154 2,716E-01 -0,5660 
     miR-183 4395380 2,719E-01 -0,5656 
     miR-520e 4373255 2,720E-01 -0,5655 
     let-7c 4373167 2,721E-01 -0,5653 
     miR-210 4373089 2,723E-01 -0,5650 
     miR-34a 4395168 2,735E-01 -0,5630 
     miR-542-3p 4378101 2,739E-01 -0,5625 
     miR-597 4380960 2,739E-01 -0,5623 
     miR-103 4373158 2,752E-01 -0,5603 
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miR-301a 4373064 2,759E-01 -0,5593 
     miR-520a-5p 4378085 2,903E-01 -0,5371 
     miR-129-3p 4373297 2,959E-01 -0,5289 
     miR-23a 4373074 3,022E-01 -0,5198 
     miR-379 4373349 3,098E-01 -0,5089 
     miR-872 4395375 3,111E-01 -0,5070 
     miR-190b 2263 3,580E-01 -0,4461 
     miR-191# 2678 4,408E-01 -0,3557 
     miR-181c# 2333 4,683E-01 -0,3295 
     miR-505# 2087 4,723E-01 -0,3257 
     miR-720 2895 4,731E-01 -0,3251 
     miR-664 2897 4,748E-01 -0,3235 
     miR-20a# 2437 4,776E-01 -0,3210 
     miR-1248 2870 4,793E-01 -0,3194 
     miR-31# 2113 4,794E-01 -0,3193 
     miR-335# 2185 4,798E-01 -0,3189 
     miR-519a 4395526 4,805E-01 -0,3183 
     miR-425# 2302 4,806E-01 -0,3182 
     miR-15b# 2173 4,843E-01 -0,3149 
     miR-106b# 2380 4,843E-01 -0,3149 
     miR-192# 2272 4,852E-01 -0,3141 
     miR-16-1# 2420 4,853E-01 -0,3140 
     miR-564 1531 4,886E-01 -0,3111 
     miR-126# 451 4,890E-01 -0,3107 
     miR-941 2183 4,946E-01 -0,3058 
     miR-744# 2325 5,033E-01 -0,2981 
     miR-1201 2781 5,054E-01 -0,2964 
     miR-548d-3p 4381008 5,065E-01 -0,2954 
     miR-200b 4395362 5,128E-01 -0,2900 
     let-7e 4395517 5,136E-01 -0,2893 
     miR-19b 4373098 5,149E-01 -0,2883 
     miR-23b 4373073 5,169E-01 -0,2866 
     miR-296-5p 4373066 5,192E-01 -0,2846 
     miR-449b 4381011 5,208E-01 -0,2833 
     miR-323-3p 4395338 5,222E-01 -0,2821 
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miR-212 4373087 5,252E-01 -0,2796 
     miR-483-5p 4395449 5,291E-01 -0,2765 
     miR-21 4373090 5,302E-01 -0,2755 
     miR-518e 4395506 5,306E-01 -0,2752 
     miR-299-5p 4373188 5,308E-01 -0,2751 
     miR-331-3p 4373046 5,322E-01 -0,2740 
     miR-193a-5p 4395392 5,325E-01 -0,2737 
     miR-15a 4373123 5,340E-01 -0,2725 
     miR-29c 4395171 5,341E-01 -0,2723 
     miR-92a 4395169 5,344E-01 -0,2722 
     miR-182 4395445 5,346E-01 -0,2720 
     miR-532-5p 4380928 5,348E-01 -0,2718 
     miR-222 4395387 5,349E-01 -0,2717 
     miR-625 4395542 5,356E-01 -0,2711 
     miR-106a 4395280 5,359E-01 -0,2709 
     has-miR-155 4395459 5,360E-01 -0,2709 
     miR-330-3p 4373047 5,361E-01 -0,2708 
     let-7g 4395393 5,361E-01 -0,2708 
     miR-491-5p 4381053 5,363E-01 -0,2706 
     miR-30b 4373290 5,367E-01 -0,2703 
     miR-142-5p 4395359 5,369E-01 -0,2701 
     miR-128 4395327 5,370E-01 -0,2700 
     miR-502-3p 4395194 5,370E-01 -0,2700 
     miR-18a 4395533 5,371E-01 -0,2700 
     miR-342-3p 4395371 5,371E-01 -0,2699 
     miR-150 4373127 5,371E-01 -0,2699 
     miR-301b 4395503 5,371E-01 -0,2699 
     miR-181c 4373115 5,382E-01 -0,2691 
     miR-132 4373143 5,385E-01 -0,2688 
     miR-362-5p 4378092 5,386E-01 -0,2688 
     miR-454 4395434 5,388E-01 -0,2686 
     miR-28-3p 4395557 5,389E-01 -0,2685 
     miR-361-5p 4373035 5,389E-01 -0,2685 
     miR-324-5p 4373052 5,391E-01 -0,2684 
     miR-195 4373105 5,393E-01 -0,2682 
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miR-200c 4395411 5,393E-01 -0,2681 
     miR-425 4380926 5,394E-01 -0,2681 
     miR-146b-5p 4373178 5,400E-01 -0,2676 
     miR-203 4373095 5,401E-01 -0,2675 
     miR-636 4395199 5,403E-01 -0,2674 
     miR-193b 4395478 5,403E-01 -0,2673 
     miR-484 4381032 5,405E-01 -0,2672 
     miR-509-3-5p 4395266 5,406E-01 -0,2671 
     miR-130b 4373144 5,406E-01 -0,2671 
     miR-328 4373049 5,406E-01 -0,2671 
     miR-326 4373050 5,407E-01 -0,2670 
     miR-320 4395388 5,409E-01 -0,2669 
     miR-17 4395419 5,416E-01 -0,2664 
     miR-28-5p 4373067 5,418E-01 -0,2662 
     miR-616 4395525 5,419E-01 -0,2661 
     miR-93 4373302 5,420E-01 -0,2660 
     miR-455-3p 4395355 5,427E-01 -0,2654 
     miR-27b 4373068 5,427E-01 -0,2654 
     miR-576-3p 4395462 5,429E-01 -0,2653 
     miR-424 4373201 5,429E-01 -0,2653 
     miR-139-5p 4395400 5,431E-01 -0,2652 
     miR-192 4373108 5,431E-01 -0,2651 
     miR-26a 4395166 5,432E-01 -0,2651 
     miR-26b 4395167 5,433E-01 -0,2650 
     miR-25 4373071 5,433E-01 -0,2649 
     miR-221 4373077 5,438E-01 -0,2646 
     miR-671-3p 4395433 5,438E-01 -0,2645 
     miR-363 4378090 5,442E-01 -0,2643 
     miR-339-3p 4395295 5,442E-01 -0,2642 
     miR-324-3p 4395272 5,443E-01 -0,2641 
     miR-500 4395539 5,445E-01 -0,2640 
     miR-98 4373009 5,451E-01 -0,2635 
     miR-518d-3p 4373248 5,452E-01 -0,2635 
     miR-186 4395396 5,453E-01 -0,2634 
     miR-489 4395469 5,454E-01 -0,2633 
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let-7f 4373164 5,455E-01 -0,2632 
     miR-197 4373102 5,455E-01 -0,2632 
     miR-130a 4373145 5,458E-01 -0,2630 
     miR-140-5p 4373374 5,460E-01 -0,2628 
     miR-148a 4373130 5,466E-01 -0,2624 
     miR-101 4395364 5,474E-01 -0,2617 
     miR-142-3p 4373136 5,481E-01 -0,2611 
     miR-551b# 2346 5,491E-01 -0,2604 
     miR-590-5p 4395176 5,492E-01 -0,2603 
     let-7a 4373169 5,497E-01 -0,2599 
     miR-140-3p 4395345 5,500E-01 -0,2597 
     miR-652 4395463 5,500E-01 -0,2597 
     miR-20b 4373263 5,519E-01 -0,2582 
     miR-422a 4395408 5,526E-01 -0,2576 
     miR-502-5p 4373227 5,531E-01 -0,2572 
     miR-532-3p 4395466 5,537E-01 -0,2568 
     miR-618 4380996 5,538E-01 -0,2567 
     miR-335 4373045 5,548E-01 -0,2559 
     miR-629 4395547 5,552E-01 -0,2556 
     miR-126 4395339 5,558E-01 -0,2551 
     miR-24 4373072 5,566E-01 -0,2544 
     miR-661 1606 5,568E-01 -0,2543 
     miR-184 4373113 5,577E-01 -0,2536 
     miR-29a 4395223 5,586E-01 -0,2529 
     miR-1 4395333 5,601E-01 -0,2517 
     let-7b 4395446 5,612E-01 -0,2509 
     miR-16 4373121 5,619E-01 -0,2504 
     miR-518b 4373246 5,633E-01 -0,2492 
     miR-187 4373307 5,691E-01 -0,2448 
     miR-365 4373194 5,729E-01 -0,2420 
     miR-9 4373285 5,738E-01 -0,2412 
     miR-20a 4373286 5,759E-01 -0,2397 
     miR-486-5p 4378096 5,805E-01 -0,2362 
     miR-1298 2861 5,827E-01 -0,2345 
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Table 7: Differential regulated miRNAs in Jurkat cell lines silenced for Notch3 relative to its 
scramble counterpart. 
Down-Regulated miRNA 
 
Up-Regulated miRNA 
miRNA Detector Code RQ (>2fold) 
 
miRNA Detector Code RQ (>2fold) 
miR-1267 2885 8,58232E-06 
 
miR-137 4373301 15352,415053 
miR-198 4395384 0,000737 
 
miR-628-5p 4395544 7946,627478 
miR-127-3p 4373147 0,007004 
 
miR-299-3p 4373189 202,319140 
miR-337-5p 4395267 0,007091 
 
miR-133b 4395358 42,648704 
miR-1298 2861 0,008838 
 
miR-99a 4373008 36,339508 
miR-124 4373295 0,009365 
 
miR-1201 2781 4,582948 
miR-539 4378103 0,058724 
 
miR-1300 2902 4,490683 
miR-449b 4381011 0,116513 
 
miR-215 4373084 4,201883 
miR-491-5p 4381053 0,124069 
 
miR-193b# 2366 4,044530 
miR-331-5p 4395344 0,128924 
 
miR-571 1613 3,174796 
miR-518f 4395499 0,137446 
 
miR-424 4373201 3,120773 
miR-122 4395356 0,139273 
 
miR-1262 2852 2,823383 
miR-129-3p 4373297 0,194106 
 
miR-500 1046 2,411622 
miR-105 4395278 0,204880 
 
miR-661 1606 2,305753 
miR-487a 4378097 0,239804 
 
miR-30a-5p 417 2,273452 
miR-200c 4395411 0,244434 
 
miR-190b 2263 2,266146 
miR-130b 4373144 0,247882 
 
miR-543 2376 2,265451 
let-7a 4373169 0,248395 
 
miR-151-5P 2642 2,251496 
miR-339-3p 4395295 0,249094 
 
miR-1260 2896 2,251487 
miR-486-5p 4378096 0,250567 
 
miR-223# 2098 2,248335 
miR-195 4373105 0,250718 
 
miR-1290 2863 2,243967 
miR-500 4395539 0,251805 
 
miR-26b# 2444 2,240106 
miR-636 4395199 0,251836 
 
miR-26a-1# 2443 2,238476 
miR-494 4395476 0,253856 
 
miR-126# 451 2,228261 
miR-744 4395435 0,254502 
 
miR-1254 2818 2,225146 
miR-27a 4373287 0,255139 
 
miR-663B 2857 2,218681 
miR-181a 4373117 0,255194 
 
miR-938 2181 2,216853 
miR-132 4373143 0,255857 
 
miR-378 567 2,210304 
miR-29b 4373288 0,255864 
 
miR-106b# 2380 2,177423 
miR-20b 4373263 0,256223 
 
miR-1296 2908 2,167619 
miR-142-3p 4373136 0,260388 
 
miR-518d-3p- 4373248 2,099646 
let-7f 4373164 0,263536 
 
miR-328 4373049 2,042388 
miR-15b 4373122 0,271889 
 
miR-194 4373106 2,041546 
miR-302a# 2381 0,295837 
 
miR-1227 2769 2,035154 
miR-522 4395524 0,426182 
    
miR-874 4395379 0,464569 
    
miR-1294 2785 0,486192 
    
miR-217 4395448 0,487889 
    
miR-501-5p 4373226 0,492347 
    
miR-17 4395419 0,496901 
    
miR-331-3p 4373046 0,497826 
    
miR-652 4395463 0,500312 
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miR-182 4395445 0,500773 
    
miR-18b 4395328 0,500893 
    
miR-519d 4395514 0,501203 
    
miR-484 4381032 0,501513 
    
miR-660 4380925 0,502092 
    
miR-362-5p 4378092 0,504181 
    
miR-425 4380926 0,504361 
    
miR-196b 4395326 0,504464 
    
miR-197 4373102 0,504837 
    
miR-149 4395366 0,504907 
    
miR-126 4395339 0,505109 
    
miR-29a 4395223 0,505239 
    
miR-455-3p 4395355 0,505315 
    
miR-29c 4395171 0,505946 
    
miR-483-5p 4395449 0,506506 
    
miR-345 4395297 0,506624 
    
miR-221 4373077 0,506681 
    
miR-363 4378090 0,506844 
    
miR-128 4395327 0,507212 
    
miR-25 4373071 0,507407 
    
miR-106b 4373155 0,507718 
    
miR-103 4373158 0,507736 
    
miR-150 4373127 0,507777 
    
miR-422a 4395408 0,507880 
    
miR-95 4373011 0,508274 
    
miR-21 4373090 0,508377 
    
miR-146a 4373132 0,508996 
    
miR-138 4395395 0,509051 
    
miR-106a 4395280 0,509280 
    
miR-20a 4373286 0,509351 
    
miR-526b 4395493 0,509899 
    
miR-324-3p 4395272 0,509902 
    
miR-30b 4373290 0,510112 
    
miR-146b-5p 4373178 0,510461 
    
miR-296-5p 4373066 0,510466 
    
miR-19a 4373099 0,510560 
    
miR-590-5p 4395176 0,510625 
    
miR-301b 4395503 0,510940 
    
miR-532-3p 4395466 0,510973 
    
miR-301a 4373064 0,511083 
    
miR-342-3p 4395371 0,511111 
    
miR-30c 4373060 0,511135 
    
miR-223 4395406 0,511350 
    
miR-28-3p 4395557 0,511471 
    
miR-26b 4395167 0,511559 
    
miR-192 4373108 0,511707 
    
miR-505 4395200 0,511900 
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miR-361-5p 4373035 0,511955 
    
miR-222 4395387 0,512022 
    
miR-320 4395388 0,512317 
    
miR-455-5p 4378098 0,512784 
    
miR-19b 4373098 0,512996 
    
miR-140-5p 4373374 0,513135 
    
miR-99b 4373007 0,513361 
    
miR-93 4373302 0,513432 
    
miR-24 4373072 0,513722 
    
miR-374a 4373028 0,514210 
    
let-7b 4395446 0,514218 
    
miR-210 4373089 0,514761 
    
miR-532-5p 4380928 0,514777 
    
miR-139-5p 4395400 0,515020 
    
miR-671-3p 4395433 0,515055 
    
miR-140-3p 4395345 0,515375 
    
miR-454 4395434 0,515641 
    
miR-26a 4395166 0,516401 
    
miR-183 4395380 0,516477 
    
miR-324-5p 4373052 0,516772 
    
miR-148a 4373130 0,516957 
    
let-7g 4395393 0,517136 
    
miR-1825 2907 0,517330 
    
miR-18a 4395533 0,517983 
    
miR-186 4395396 0,518778 
    
miR-374b 4381045 0,519032 
    
let-7e 4395517 0,519188 
    
miR-9 4373285 0,519737 
    
miR-92a 4395169 0,520252 
    
miR-28-5p 4373067 0,520277 
    
miR-492 4373217 0,521188 
    
let-7d 4395394 0,522238 
    
miR-213 516 0,536599 
    
miR-942 2187 0,545913 
    
miR-517a 4395513 0,546139 
    
miR-629 1562 0,553075 
    
miR-340# 2259 0,553100 
    
rno-miR-7# 1338 0,553745 
    
miR-425# 2302 0,554031 
    
miR-130b# 2114 0,556442 
    
miR-941 2183 0,558926 
    
miR-520a-3p 4373268 0,589622 
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5. Discussion  
Canonically, Notch acts as a membrane bound co-transcription factor that is released in 
response to ligand binding by two proteases acting sequentially. The freed intracellular domain 
enters the nucleus, where it interacts with a DNA-bound protein complex to activate 
transcription of selected target genes. Despite, dysregulated Notch signaling constitutes one of 
the major signaling pathway in inducing T-ALL, it has not been fully elucidated  all the target 
genes of Notch including miRNAs, how these target are regulated and consequence of this in 
T-ALL development. Thus in this work we aimed  to understand if Notch3 was able to 
regulate some miRNAs, both in-vivo and in cell models which were modulated with different 
expression of Notch3. Here we utilized different cell models from mouse to human and 
modulated the expression of Notch3 in order to get more universal miRNAs which could be 
regulated by Notch3 in different cell contexts. The miRNAs profiling revealed 7 significant 
miRNAs which were positively regulated by modulation of Notch3. Out of these miRNAs, 
miR-223 exhibited the most dynamic up and down-regulation after Notch3 overexpression or 
knockdown. Single miR-223 validation by RT-PCR in our models confirmed the regulation of 
miR-223 in response to modulation of Notch3, thus the result obtained by the array analysis 
was not false. Although the identification of differentially regulated genes by microarray 
analysis is important to understand transcriptional networks, it provides only limited 
information on the regulation of genes as microarray analysis cannot distinguish between 
direct and indirect targets. The presence of a CSL binding site in the promoter of a gene could 
be an indicative of direct regulation by Notch signaling. Promoter analysis of miR-223 
revealed the conserved CSL/RBPJκ binding site which was nested with NFκB. Consistent with 
our finding of miR-223 overexpression in Notch3 models, a recent study identified miR-223 as 
the most abundant miRNA in T-ALL patient samples and revealed its oncogenic role by virtue 
of its ability to accelerate Notch-induced T-ALL in a murine model mice [188]. Another 
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studies identified miR-223 as overexpressed in CD4
+
 naive T-lymphocytes from individuals 
affected with rheumatoid arthritis [211]. These evidences made us to focus on miR-223 in 
relation on how it was regulated by Notch3. As expected, the luciferase assay on mir-223 
promoter revealed a direct regulation by Notch3 transcriptional  complex, but interestingly 
also p65 induced the promoter activation as the CSL/RBPjK binding site on miR-223 was 
nested with NFκB. Thus revealing that miR-223 promoter could be regulated in part directly 
by Notch3 and indirectly by activating NFκB signaling pathway during T Lymphocyte 
development. This is also true as our lab has already published that in Notch3 transgenic mice 
which develop symptoms of T-ALL there is constitutive activation of NFκB [61] [189]. As 
miR-223 has been shown to exert diverse role depending on the cell context  [212] [213] [214] 
[215] [200] so it would be unlikely that its transcriptional regulation is controlled by single 
transcriptional factor. Previous reports have been already described about the transcriptional 
regulation of miR-223 by CEBPα , NFI-A [193] P.U1 [194] and E2F1 [216], but all these 
studies were done on Acute Myleoid Leukemia (AML). Although mir-223  has been reported 
to be more up regulated in AML compared to ALL, [217], it cannot be assumed that its 
expression is fully repressed in ALL patients, thus there must be some mechanism which are 
responsible for regulation of miR-223 in ALL patients apart from myeloid specific 
transcription factors such as CEBPa & P.U1. Here we report for the first time that miR-223 
regulation in T-ALL context was dependent on Notch3 and NFκB signaling. The luciferase 
assay on the mutant of miR-223 promoter deleted for NFκB/CSL/ RBPjK consensus site and 
the Chip analysis gave us the strong evidences that p65 really played a direct role in regulation 
of miR-223 at transcriptional level. Moreover the luciferase assay on miR-223 promoter with 
p65 in presence of IkBα-sr and pharmacological approach such as TPA (which is known to 
induce NFκB signaling pathway) and BAY-11-7082 (which is known to repress NFκB 
pathway) on endogenous miR-223 in Jurkat cell lines justified more appropriately that p65 was 
involved in miR-223 regulation. 
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As we were able to show that miR-223 could directly regulate FBXW7 by transient 
transfecting mimic and antimiR-223 in Jurkat cell lines and this regulation affected the 
stabilization of FBXW7 targets such as c-myc, cyclin-E , Notch1 etc which were already 
reported to be involved in cell-cycle, proliferation and growth, suggesting the oncogenic role 
of miR-223 in T-ALL through repression of tumor suppressor FBXW7. Previous report have 
already suggested that down modulation of Notch signaling in T-ALL could result in growth 
arrest by modulating Notch direct target gene such as c-Myc, but till now no report have 
highlighted the relationship on Notch3 and miRNAs in cell proliferation and growth. Our 
study could suggest  another aspect by which Notch could regulate cell growth and 
proliferation in T-ALL by regulating mir-223 through p65. This functional aspect of miR-223 
modulation in cell cycle in T-ALL was confirmed when mimic of miR-223 showed an increase 
in cell growth and increase in percentage of cells in S phase compared to negative control by 
FACS analysis on Jurkat cell lines. To deepen our knowledge on functional aspect of miR-223 
in growth regulation, we utilized Jurkat cell lines which were stably deleted for IKKᵞ. These 
cell lines showed decrease phosho-p65 and less induction of miR-223 when compared with 
Jurkat wild type. The stable clone of IKKᵞ -/-, showed decrease cell growth as expected, 
compared to Jurkat wild type when they were kept in culture for 14 days. Although the its 
cannot be excluded that the effect of IKKᵞ deletion on other signaling pathways can also be 
responsible for decrease in cell growth. 
We had already validated that down modulation of Notch3 specifically by Sh or siRNA in 
Molt3 and Jurkat leads to down modulation of miR-223. Keeping this aspect we tried to use 
DAPT (GSI- IX) (γ-Secretase Inhibitor-IX) to decrease miR-223 expression by blocking 
Notch signaling, but unexpectedly we got an opposite result as DAPT instead of suppressing 
had an inductive effect on miR-223 expression both in Jurkat and Molt-3 T-ALL cell lines. 
Keeping this aspect in consistent, a very recent publication revealed that GSI-XXI Compound 
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E treatments increased miR-223 levels in several T ALL cell lines such as Jurkat and RPMI 
8402 cells and by this they suggested that active Notch signaling could repress miR-223 
expression by regulating an intermediate repressor protein. In this study the authors 
hypothesized Notch signaling positively regulate the expression of some transcriptional 
repressor of miR-223 and therefore GSI-XXI treatments inhibiting Notch signaling, 
indirectly, leads the increased miR-223 expression. Unfortunately, the authors didn’t identify 
the specific molecules responsible of the miR-223 gene regulation. Moreover, the authors 
demonstrated that neither Hes1 and Myc are involved in this mechanism as enforced 
expression of both, did not prevent GSI-XXI-dependent miR-223 overexpression [210]. The 
regulation miR-223 by DAPT treatment was completely opposite to what we observed when 
we down modulated Notch3 by Sh or siRNA, without modulating other Notch receptors. As 
the specific silencing of Notch3 is more reliable to see the effect of Notch3 compared to 
DAPT treatment. This results suggest that GSI could not be used as a sole compound to better 
understand the Notch signaling mechanism exerted by different Notches  as GSI treatment 
block all Notch receptors making it difficult to distinguish the effect of different Notch 
receptors on signaling, and also being a chemical compound it cannot be excluded that it can 
have diverse effect on different proteins and signaling pathway. To solve this dilemma we 
tried to focus on status of NFκB in DAPT treated and untreated Jurkat and Molt3 cell lines. 
To our surprise we saw an activated p65 (Phosho-p65) in DAPT treated cell lines thus 
resolving our problem of why DAPT could up regulated miR-223. But we were not able to 
find out how DAPT treatment leads to phosphoryltion of p65, and thus its need further 
investigation. Utilising this finding we used Jurkat IKKᵞ-/- cell lines for DAPT treatment, as in 
this cell lines, we were blocking both, Notch mediated proliferation by blocking Notch and 
miR-223 mediated proliferation by blocking NFκB through IKKᵞ deletion, we saw decrease 
cell growth in Jurkat IKKᵞ-/- treated. Thus making resistance T-ALL sensitive, by combination 
of Notch and NFκB inhibition. This could give us the reason why some T-ALL patient or Cell 
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lines are resistant to GSI treatment. In this scenario our results strongly suggest a 
combinatorial therapeutic approach aimed to block, both Notch  and NFκB pathway for the 
treatment of childhood T-ALL. 
Moreover,  it has already been known that Acute lymphoblastic leukemia (ALL) of T-cell 
type is a heterogeneous group of ALL at least by immunophenotyping [218] and recently the 
overexpression of miR-223 was shown to be used to identify  a subset of adult T-cell acute 
lymphoblastic leukemia with myeloid-like gene features [214]. Thus it could be possible that 
other subset of T-ALL overexpress miR-223. In this regard, our finding could give a new 
point of view to  better understand the mechanistic event undergoing inside the subset of T-
ALL, making it possible to design the more effective combinatorial drugs.  
Considering another aspect of miRNAs in regulation, a recent report has shown that miRNAs 
can be secreated inside microvesicle and can be transported to other distant target cells by  
pheripheral blood to induce their effect on that targets. Among them miR-223 was identified 
as one of the miRNA which was also secreted by macrophage-derived microvesicles 
transported to target cells and was functionally active [219]. Thus it would be interesting to 
understand if the same effect is seen in T-ALL, in which the miR-223 secreated by the 
Lymphocytes of T-ALL is transported by microvesciles to the target cell in the 
microenvironment, thus making the cells in microenvironment more potent for growth which 
in turn can promote the T-ALL tumorogenisis . 
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6. Conclusion and Future direction:- 
In this study we identified 7 miRNAs which were regulated by Notch3 modulation in 
different Models. Among them the induction of miR-223 was most pronounced. Previous 
study had already identified the transcriptional regulation of miR-223 by CEBPα and PU.1 in 
Myeloid lineage . Recently miR-223 was shown to be up-regulated in T-ALL patients and 
also in Notch1 over-expressing transgenic mice. Thus suggesting some other transcriptional 
regulators of this miR in T-ALL context. Our study found a novel conserved CSL/RBPJκ 
binding site which was nested to NFκB consensus, in its putative promoter region. The 
luciferase assay on the wild type and mutated promoter construct for RBPJκ/NFκB binding 
site showed  the regulation by both NFκB & Notch3 signallings. Consistently, endogenous 
ChIP assay confirmed direct involvement of  NFκB in the regulation of miR-223. Moreover, 
ectopic expression of miR-223 strongly down-regulated the tumor suppressor FBXW7, thus 
up-regulating its targets such as c-Myc, Cyclin-E, known to be involved in proliferation, 
while the opposite effects was seen when antagomiR was used. Transient transfection of miR-
223 affect Jurkat cell growth as revealed by increased cell number and percentage of cells in S 
phase of cell cycle. Interestingly, GSI resistant T-ALL cell lines treated with GSI showed 
increase in miR-223 expression and NFκB activation without affecting their proliferation rate. 
The same cell lines deleted for NFκB pathway, showed less expression of miR-223 when 
compared with wild type and lost their ability to resist GSI treatment, suggesting the 
involvement of miR-223 in the mechanism of GSI resistivity. In this regard we are investing 
the miR-223 expressing in human TALL cell lines, and its effect in cell proliferation, where 
we are using the combinatorial drugs to block both Notch and NFκB pathways. 
More over we found miR-223 to be highly expressed in all the human TALL patient analysed,  
thus accessing this miRNA as a novel therapeutic target for T-ALL treatment. 
As, our results suggest the involvement of miR-223 in development of T-ALL leukemia and 
its role in GSI resistivity, thus compelling us to go further in details of its functional role. In 
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this regard we are generating human T-ALL cell lines stably overexpressing / silencing miR-
223 by Lentivirus vectors to magnify the functional effect as obtained by transient 
transfection.  
Overall our study provide an insight into the regulatory mechanism of miR-223 in Notch 
induced T-ALL, and its role in GSI restivity. The combinatorial therapeutics or therapeutic 
targeting of oncogenic miRNAs in leukemia can give an edge to the pharmacological therapy, 
where the conventional protocols show their limits of action and can obviate the toxicity 
associated to the classical chemotherapy approaches. 
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